



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 166626

TO: Ralph J Gitomer
Location: rem/3D65/3E71
Art Unit: 1651
Friday, June 10, 2005

Case Serial Number: 10/615966

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

=> d his full

(FILE 'HOME' ENTERED AT 07:50:20 ON 10 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 07:50:59 ON 10 JUN 2005

E WATKINS S/AU
L1 26 SEA ABB=ON PLU=ON ("WATKINS S"/AU OR "WATKINS S M"/AU)
E WATKINS STEVEN/AU
L2 24 SEA ABB=ON PLU=ON ("WATKINS STEVEN"/AU OR "WATKINS STEVEN
M"/AU OR "WATKINS STEVEN MICHAEL"/AU)
E WATKINS STEPHEN/AU
L3 10 SEA ABB=ON PLU=ON ("WATKINS STEPHEN"/AU OR "WATKINS STEVE"/AU
)
L4 12 SEA ABB=ON PLU=ON LIPOMICS/CS,PA
L5 1 SEA ABB=ON PLU=ON (US2002-436192# OR US2002-424949# OR
US2002-401684# OR US2002-373912# OR US2002-363587#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 07:54:30 ON 10 JUN 2005

FILE 'HCAPLUS' ENTERED AT 07:54:32 ON 10 JUN 2005

L6 TRA L5 1- RN : 20 TERMS

FILE 'REGISTRY' ENTERED AT 07:54:32 ON 10 JUN 2005

L7 20 SEA ABB=ON PLU=ON L6

FILE 'WPIX' ENTERED AT 07:54:36 ON 10 JUN 2005

L8 1 SEA ABB=ON PLU=ON (US2002-436192# OR US2002-424949# OR
US2002-401684# OR US2002-373912# OR US2002-363587#)/AP,PRN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 07:55:13 ON 10 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jun 2005 VOL 142 ISS 25

FILE LAST UPDATED: 9 Jun 2005 (20050609/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 15 tot

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:757811 HCAPLUS
DN 139:271092
ED Entered STN: 26 Sep 2003
TI Novel metabolic targets and markers
IN Watkins, Steven M.; Baillie, Rebecca A.
PA Lipomics Technologies, Inc., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent

Search done by Noble Jarrell

LA English
 IC ICM C12N
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 2, 9

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078574	A2	20030925	WO 2003-US7242	20030307 <--
	WO 2003078574	A3	20040219		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2477909	AA	20030925	CA 2003-2477909	20030307 <--
	US 2004024065	A1	20040205	US 2003-383850	20030307 <--
	EP 1490076	A2	20041229	EP 2003-744631	20030307 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-363587P	P	20020311	<--	
	US 2002-373912P	P	20020419	<--	
	US 2002-401684P	P	20020806	<--	
	US 2002-424949P	P	20021108	<--	
	US 2002-436192P	P	20021224	<--	
	WO 2003-US7242	W	20030307		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003078574	ICM	C12N
WO 2003078574	ECLA	A61K031/00; A61K031/51; A61K031/519; A61K038/22; A61K038/27; C12N009/10A <--
US 2004024065	NCL	514/560.000
	ECLA	A61K031/00; A61K031/51; A61K031/519; A61K038/22; A61K038/27; C12N009/10A <--

AB The present invention is based, in part, on the discovery that certain metabolites or metabolic pathways can be used as diagnostic or therapeutic markers. For example, phosphatidylethanolamine-N-methyltransferase (PEMT) activity and other metabolic activities or markers associated therewith can be used either as markers for diagnosing various conditions or as targets for therapeutic treatment of various disease conditions. In one embodiment, the present invention provides a method for regulating the level of a fatty acid in a system. The method includes decreasing the CDP-choline activity in the system. In still another embodiment, the present invention provides a method for regulating a lipoprotein component ratio in a system. The method includes regulating the PEMT activity in the system whereby regulating the lipoprotein component ratio in the system, wherein the lipoprotein component ratio is selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine. In another embodiment, the present invention provides a method of assessing the d. of a lipoprotein in a system. In yet another embodiment, the present invention provides a method for treating or preventing a cardiovascular or neurol. condition.

ST phosphatidylcholine methyltransferase metabolic pathway disease treatment
 IT Brain, disease
 (Alpers' disease; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT Congenital malformations
 (Arnold-Chiari Malformation; phosphatidylethanolamine-N-

- methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(Asperger's Syndrome; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(Gilles de la Tourette syndrome; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain
Heart
Intestine
Liver
Mammary gland
(PEMT of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(Pick's disease; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(Rett syndrome; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Disease, animal
(Shy-Drager syndrome; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Nuclear receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists, antitumor activity of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Antiarteriosclerotics
(antiatherosclerotics; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Estrogens
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antiestrogens, infertility from; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Peroxisome proliferators
(antitumor activity of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Heart, disease
(arrhythmia; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Eicosanoids
Thyroid hormones

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(assessment of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Allergy
(atopy, congenital malformations from; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Heart, disease
(attack; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(attention deficit hyperactivity disorder; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(autism; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(calcinosis; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Ischemia
(cardiac; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Heart, disease
(cardiomyopathy; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Movement disorders
(cerebral palsy; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Paralysis
(childhood alternating hemiplegia; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Apolipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol esters; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Intestine, neoplasm
(colon; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Diabetes mellitus
(congenital malformations from; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

- IT Artery, disease
(coronary; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Sperm
(decreased motility; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Nerve, disease
(degeneration; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Bone, disease
(demineralization; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(diffuse Lewy body disease; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Calcification
(disorder, calcinosis, cerebral; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Immunity
(disorder, congenital malformations from; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Carcinoma
(esophageal squamous cell; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Kidney, disease
(failure; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Blood plasma
(fatty acids and lipoproteins of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Animal tissue
(fatty acids of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Phosphatidylcholines, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fatty acids of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Liver, disease
(fatty; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

- IT Embryo, animal
(fetus, treatment of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d.; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Head, disease
(holoprosencephaly; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(hydranencephaly; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(hydrocephalus, Dandy Walker Syndrome; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Milk
(increase in production of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Development, mammalian postnatal
(infant, treatment of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Human immunodeficiency virus
(infection, parenterally acquired; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Intestine, disease
(inflammatory; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(intermediate-d.; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Heart, disease
(ischemia; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Neuronal ceroid lipofuscinosis
(juvenile; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and

- lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Transplant and Transplantation
(liver; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (low-d.; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Fertility
(male, disorder; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Head, disease
(microcephaly; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Nerve, disease
(motor; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Nervous system, disease
(multiple system atrophy; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Mental disorder
(neurotic depression; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (of phosphatidylcholines; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT AIDS (disease)
(parenterally acquired; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarrhythmics
Anticholesteremic agents
Antihypertensives
Antiobesity agents
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents
Atherosclerosis
Autoimmune disease
Cardiovascular agents
Cardiovascular system, disease
Chylomicrons
Cirrhosis
Cockayne's syndrome

Congenital malformations
 Diagnosis
 Fetal alcohol syndrome
 Fragile X syndrome
 Human
 Hypercholesterolemia
 Hyperglycemia
 Hypertension
 Hyperthyroidism
 Hypertriglyceridemia
 Hypolipemic agents
 Hypothyroidism
 Infection
 Inflammation
 Neoplasm
 Nervous system, disease
 Obesity
 Osteoporosis
 Pancreas, neoplasm
 Parkinson's disease
 Phenylketonuria
 Poliomyelitis
 Prostate gland, neoplasm
 Rheumatoid arthritis
 Skin, disease
 Teratogenesis
 Thyroid gland, neoplasm
 (phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Fatty acids, biological studies
 Lipids, biological studies
 Lipoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Estrogens
 Sex hormones
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polyunsatd.; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Paralysis
 (pseudobulbar; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (saturated; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
 IT Spinal column, disease
 (spina bifida; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

- IT Nervous system, disease
(spinocerebellar ataxia; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Esophagus, neoplasm
(squamous cell carcinoma; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(stroke; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Heart
Liver
(toxicity, PEMT of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Liver
(transplant; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lactation
(treatment in; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Brain, disease
(tuberous sclerosis; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(very-low-d.; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Infection
(viral, HIV, parenterally acquired; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Adrenoceptor agonists
(β 1-; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Adrenoceptor agonists
(β 2-; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT Adrenoceptor agonists
(β 3-; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)
- IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(assessment of; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and

lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 6027-13-0, Homocysteine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(in lipoproteins determination; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 262-12-4D, Dibenzo[b,e][1,4]dioxin, chloro derivs.
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(infertility from; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of apolipoproteins; phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-88-5D, Cholesterol, esters 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 373-49-9 506-17-2 506-32-1 979-92-0, S-Adenosylhomocysteine 987-78-0, CDP-choline 6217-54-5 10417-94-4 37256-91-0, Phosphatidylethanolamine-N-methyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 9002-72-6, Growth hormone 29908-03-0
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

IT 59-30-3, Folic acid, biological studies 59-67-6, Niacin, biological studies 8059-24-3, Vitamin B6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphatidylethanolamine-N-methyltransferase (PEMT) as metabolic target and marker to regulate fatty acid levels and lipoprotein component ratio for disease treatment in relation to CDP-choline)

=> b reg

FILE 'REGISTRY' ENTERED AT 07:55:26 ON 10 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2005 HIGHEST RN 852020-24-7
DICTIONARY FILE UPDATES: 9 JUN 2005 HIGHEST RN 852020-24-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Search done by Noble Jarrell

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l7 tot

L7 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 37256-91-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Methyltransferase, phosphatidylethanolamine (9CI) (CA INDEX NAME)
OTHER NAMES:
CN E.C. 2.1.1.17
CN Lipid methyl transferase
CN Phosphatidylethanolamine methyltransferase
CN Phosphatidylethanolamine N-methyltransferase
CN Phosphatidylethanolamine-N-methylase
CN Phosphatidylethanolamine-S-adenosylmethionine methyltransferase
CN S-Adenosylmethionine-phosphatidylethanolamine methyltransferase
DR 9068-27-3
MF Unspecified
CI MAN
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
322 REFERENCES IN FILE CA (1907 TO DATE)
322 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 29908-03-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-, inner salt (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Adenosine, 5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt, (3S)-
CN Adenosine, 5'-[(L-3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt (8CI)
CN Methionine, S-adenosyl- (6CI)
OTHER NAMES:
CN Active methionine
CN Ademethionine
CN AdoMet
CN Donamet
CN L-Methionine, S-adenosyl-
CN L-S-Adenosylmethionine
CN S Amet
CN S-Adenosyl-L-methionine
CN SAME
FS STEREOSEARCH
DR 23095-97-8, 2613-02-7, 86522-35-2, 86866-89-9, 5134-37-2, 28378-99-6
MF C15 H22 N6 O5 S
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,


BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, PS, RTECS*, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



3656 REFERENCES IN FILE CA (1907 TO DATE).

111 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3659 REFERENCES IN FILE CAPLUS (1907 TO DATE)

51 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN

RN 10417-94-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z) - (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,8,11,14,17-Eicosapentaenoic acid (6CI)

CN 5,8,11,14,17-Eicosapentaenoic acid, (all-Z) - (8CI)

OTHER NAMES:

CN (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid

CN (all-cis)-5,8,11,14,17-Eicosapentaenoic acid

CN (all-Z)-Δ5,8,11,14,17-Eicosapentaenoic acid

CN (all-Z)-5,8,11,14,17-Eicosapentaenoic acid

CN Eicosapentaenoic acid

CN EPA

CN Icosapent

CN Icosapentaenoic acid

CN Timnodonic acid

FS STEREOSEARCH

DR 25377-48-4

MF C20 H30 O2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, MRCK*, PATDPASPC, PHAR, PROMT, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO

Double bond geometry as shown.



Search done by Noble Jarrell

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8542 REFERENCES IN FILE CA (1907 TO DATE)
193 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8554 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 9004-10-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Insulin (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Actrapid
CN Actrapid HM
CN Actrapid MC
CN Decurvon
CN Dermulin
CN Endopancrine
CN Exubera
CN HMR 4006
CN Iletin
CN Insular
CN Insulin Injection
CN Insulyl
CN Intesulin B
CN Iszilin
CN Mixtard
CN Musulin
DR 8049-67-0, 8049-95-4, 9004-12-0, 9037-76-7, 9045-63-0, 9045-65-2,
9045-66-3, 9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8,
37243-75-7, 37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,
CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB,
IMSCOSEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR,
PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103300 REFERENCES IN FILE CA (1907 TO DATE)
1895 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103374 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 9002-72-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Somatotropin (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Adenohypophyseal growth hormone
CN Anterior hypophyseal growth hormone
CN Anterior pituitary growth hormone
CN GH
CN Growth hormone
CN Hypophyseal growth hormone
CN Phyol
CN Phylone
CN Pituitary growth hormone

CN SH
CN Somacton
CN Somatotrophic hormone
CN Sotropin H
CN STH
DR 9042-17-5, 9061-43-2, 9067-08-7
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

32468 REFERENCES IN FILE CA (1907 TO DATE)
617 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
32490 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 8059-24-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Adermine
CN Vitamin H
DR 12001-78-4
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSNB, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NIOSHTIC, PROMT, TOXCENTER, USPAT2, USPATFULL
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


8931 REFERENCES IN FILE CA (1907 TO DATE)
175 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8939 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 6217-54-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,7,10,13,16,19-Docosahexaenoic acid, (all-Z)- (8CI)
CN Docosahexaenoic acid (6CI)
OTHER NAMES:
CN (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoic acid
CN (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
CN (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexenoic acid
CN (all-Z)-4,7,10,13,16,19-Docosahexaenoic acid
CN Δ 4,7,10,13,16,19-Docosahexaenoic acid
CN 4-cis,7-cis,10-cis,13-cis,16-cis,19-cis-Docosahexaenoic acid

Search done by Noble Jarrell

CN all-cis-4,7,10,13,16,19-Docosahexaenoic acid
 CN all-Z-Docosahexaenoic acid
 CN Cervonic acid
 CN DHA
 CN Doconexent
 CN Marinol D 50TG
 FS STEREOSEARCH
 DR 25377-50-8
 MF C22 H32 O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN,
 CHEMCATS, CIN, CSCHM, EMBASE, IMSRESEARCH, MRCK*, PATDPASPC, PROMT,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9074 REFERENCES IN FILE CA (1907 TO DATE)
 158 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 9084 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 6027-13-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN L-Homocysteine (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Butyric acid, 2-amino-4-mercapto-, L- (8CI)
 OTHER NAMES:
 CN (S)-2-Amino-4-mercaptobutanoic acid
 CN (S)-Homocysteine
 CN 2-Amino-4-mercapto-L-butyric acid
 CN 2-Amino-4-mercaptobutyric acid
 CN Butanoic acid, 2-amino-4-mercapto-, (S)-
 CN Homocysteine
 CN NSC 43117
 FS STEREOSEARCH
 DR 454-28-4, 1867-00-1
 MF C4 H9 N O2 S
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGU,
 EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PIRA,
 PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


5572 REFERENCES IN FILE CA (1907 TO DATE)
 104 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 5579 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 987-78-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl]
 ester, inner salt (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Choline, hydroxide, 5'-ester with cytidine 5'-(trihydrogen pyrophosphate),
 inner salt (8CI)
 CN Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl]
 ester, hydroxide, inner salt
 OTHER NAMES:
 CN Audes
 CN CDP-choline
 CN Cereb
 CN Choline 5'-cytidine diphosphate
 CN Choline cytidine diphosphate
 CN Citicholine
 CN Citicoline
 CN Citidoline
 CN Citifar
 CN Colite
 CN Corenalin
 CN Cyscholin
 CN Cytidine 5'-(choline diphosphate)
 CN Cytidine 5'-(cholinylyl pyrophosphate)
 CN Cytidine 5'-diphosphate choline
 CN Cytidine 5'-diphosphocholine
 CN Cytidine choline diphosphate
 CN Cytidine diphosphate choline
 CN Cytidine diphosphate choline ester
 CN Cytidine diphosphocholine
 CN Cytidine diphosphorylcholine
 CN Cytidoline
 CN Difosfocin
 CN Emicholine F
 CN Ensign
 CN Haocolin
 CN Hornbest
 CN Neucolis
 CN Nicholin
 CN Nicolin
 CN Niticolin
 CN NSC 122002
 CN Reagin
 CN Recofnan
 CN Recognan
 CN Rexort
 CN Sintoclar
 CN Somazina
 CN Somazine
 CN Suncholin
 FS STEREOSEARCH

Search done by Noble Jarrell

DR 769081-33-6, 1477-47-0, 64143-42-6
 MF C14 H26 N4 O11 P2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
 IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
 NAPRALERT, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, TOXCENTER, USAN,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

882 REFERENCES IN FILE CA (1907 TO DATE)
 16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 882 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 979-92-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Adenosine, 5'-S-(3-amino-3-carboxypropyl)-5'-thio-, L- (8CI)
 CN Homocysteine, S-adenosyl-, L- (6CI, 7CI)
 OTHER NAMES:
 CN Adenosyl-L-homocysteine
 CN Adenosylhomocysteine
 CN L-S-Adenosylhomocysteine
 CN S-Adenosyl-L-homocysteine
 CN S-Adenosylhomocysteine
 FS STEREOSEARCH
 DR 120220-04-4, 15519-61-6, 21593-56-6, 22620-01-5, 361436-44-4
 MF C14 H20 N6 O5 S
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,
 CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, PROMT, SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1213 REFERENCES IN FILE CA (1907 TO DATE)
 108 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1214 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 506-32-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 5,8,11,14-Eicosatetraenoic acid, (5Z,8Z,11Z,14Z)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 5,8,11,14-Eicosatetraenoic acid, (all-Z)- (8CI)
 OTHER NAMES:
 CN (all-Z)-5,8,11,14-Eicosatetraenoic acid
 CN 5,8,11,14-all-cis-Eicosatetraenoic acid
 CN 5-cis,8-cis,11-cis,14-cis-Eicosatetraenoic acid
 CN 5Z,8Z,11Z,14Z-Eicosatetraenoic acid
 CN all-cis-5,8,11,14-Eicosatetraenoic acid
 CN arachidonate
 CN Arachidonic acid
 CN cis-Δ5,8,11,14-Eicosatetraenoic acid
 FS STEREOSEARCH
 DR 10417-93-3, 929-92-0
 MF C20 H32 O2
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PATDPASPC, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


28996 REFERENCES IN FILE CA (1907 TO DATE)
 2280 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 29019 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

132 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 506-17-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 11-Octadecenoic acid, (11Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 11-Octadecenoic acid, (Z)- (8CI)
CN 11-Octadecenoic acid, cis- (6CI)
OTHER NAMES:
CN (Z)-11-Octadecenoic acid
CN Δ 11-cis-Octadecenoic acid
CN 11(Z)-Octadecenoic acid
CN 11-cis-Octadecenoic acid
CN 11-cis-Vaccenic acid
CN 11Z-Octadecenoic acid
CN Asclepic acid
CN cis- Δ 11-Octadecenoic acid
CN cis-11-Octadecenoic acid
CN cis-11-Vaccenic acid
CN cis-Vaccenic acid
CN cis-Vaccenic acid
FS STEREOSEARCH
MF C18 H34 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHM, DETHERM*, IPA,
MEDLINE, NIOSHTIC, PROMT, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2687 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2694 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 373-49-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 9-Hexadecenoic acid, (9Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9-Hexadecenoic acid, (Z)- (8CI)
CN Palmitoleic acid (7CI)
OTHER NAMES:
CN (Z)-9-Hexadecenoic acid
CN 9-cis-Hexadecenoic acid
CN 9-Hexadecenoic acid
CN 9Z-Hexadecenoic acid
CN 9Z-Hexadecenoic acid
CN cis- Δ 9-Hexadecenoic acid
CN cis-9-Hexadecenoic acid
CN cis-Palmitoleic acid
CN Oleopalmitic acid
CN Zoomeric acid
FS STEREOSEARCH

Search done by Noble Jarrell

MF C16 H30 O2
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, NIOSHTIC, PATDPASPC, PIRA, PROMT, SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9109 REFERENCES IN FILE CA (1907 TO DATE)
 148 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 9129 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 262-12-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Dibenzo[b,e][1,4]dioxin (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Dibenzo-p-dioxin (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN Dibenzo[1,4]dioxin
 CN Diphenylene dioxide
 CN Oxanthrene
 CN Phenodioxin
 FS 3D CONCORD
 DR 343946-29-2
 MF C12 H8 O2
 CI COM, RPS
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DETHERM*, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VTB
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


13257 REFERENCES IN FILE CA (1907 TO DATE)
 12408 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13264 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN

Search done by Noble Jarrell

RN 60-33-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,12-Octadecadienoic acid (Z,Z)-
CN Linoleic acid (8CI)
OTHER NAMES:
CN (9Z,12Z)-9,12-Octadecadienoic acid
CN (Z,Z)-9,12-Octadecadienoic acid
CN α -Linoleic acid
CN 9,12-Octadecadienoic acid, (Z,Z)-
CN 9-cis,12-cis-Linoleic acid
CN 9Z,12Z-Linoleic acid
CN 9Z,12Z-Octadecadienoic acid
CN all-cis-9,12-Octadecadienoic acid
CN cis,cis-Linoleic acid
CN cis- Δ 9,12-Octadecadienoic acid
CN cis-9,cis-12-Octadecadienoic acid
CN Emersol 315
CN Extra Linoleic 90
CN Linolic acid
CN Polylin 515
CN Unifac 6550
FS STEREOSEARCH
MF C18 H32 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

33431 REFERENCES IN FILE CA (1907 TO DATE)
1393 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33476 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 59-67-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotinic acid (7CI, 8CI)
OTHER NAMES:
CN β -Pyridinecarboxylic acid
CN 3-Carboxypyridine
CN 3-Carboxypyridine
CN 3-Pyridylcarboxylic acid
CN Akotin
CN Apelagrin
CN Daskil

Search done by Noble Jarrell


CN E 375
 CN Efacin
 CN Enduracin
 CN Linic
 CN Niac
 CN Niacin
 CN Niacor
 CN Niaspan
 CN Nicacid
 CN Nicangin
 CN Nico-Span
 CN Nicobid
 CN Nicodelmine
 CN Nicolar
 CN Niconacid
 CN Nicosan 3
 CN Nicotinipca
 CN Nicyl
 CN NSC 169454
 CN Nyclin
 CN Pellagrin
 CN Pelonin
 CN Slo-niacin
 CN SR 4390
 CN Vitamin B5
 CN Wampocap
 FS 3D CONCORD
 DR 123574-58-3
 MF C6 H5 N O2
 CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
 CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*,
 HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*,
 MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, PROUSDDR, PS,
 RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2,
 USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15519 REFERENCES IN FILE CA (1907 TO DATE)

710 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

15534 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN

RN 59-30-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Glutamic acid, N-[4-[[[2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN Folic acid (8CI)

OTHER NAMES:

Search done by Noble Jarrell

CN Acifolic
 CN Cytofol
 CN Dosfolat B activ
 CN Folacid
 CN Folacin
 CN Folbal
 CN Folcidin
 CN Foldine
 CN Folettes
 CN Foliamin
 CN Folicet
 CN Folipac
 CN Folsan
 CN Folsaure
 CN Folsav
 CN Folvite
 CN Incafollic
 CN Liver Lactobacillus casei factor
 CN Millafol
 CN NSC 3073
 CN PGA
 CN Pteroyl-L-glutamic acid
 CN Pteroyl-L-monoglutamic acid
 CN Pteroylglutamic acid
 CN Pteroylmonoglutamic acid
 CN Vitamin Bc
 CN Vitamin Be
 CN Vitamin M
 FS STEREOSEARCH
 DR 33609-88-0
 MF C19 H19 N7 O6
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


15099 REFERENCES IN FILE CA (1907 TO DATE)
 1087 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 15114 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 57-88-5 REGISTRY

Search done by Noble Jarrell

ED Entered STN: 16 Nov 1984
 CN Cholest-5-en-3-ol (3 β) - (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Cholesterol (8CI)
 OTHER NAMES:
 CN (-)-Cholesterol
 CN Δ^5 -Cholesten-3 β -ol
 CN 3 β -Hydroxycholest-5-ene
 CN 5:6-Cholesten-3 β -ol
 CN Cholest-5-en-3 β -ol
 CN Cholesterin
 CN Cholesteryl alcohol
 CN Dythol
 CN Lidinit
 CN Lidinite
 CN NSC 8798
 CN Provitamin D
 FS STEREOSEARCH
 DR 849593-11-9, 732297-95-9, 793670-51-6, 80356-14-5, 80356-33-8,
 209124-38-9, 218965-24-3, 262418-13-3, 378185-03-6, 676322-57-9
 MF C27 H46 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM*,
 DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT,
 IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLQOM*,
 PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2,
 USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

109100 REFERENCES IN FILE CA (1907 TO DATE)
 9641 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 109177 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 57-11-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Octadecanoic acid (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 1-Heptadecanecarboxylic acid
 CN 17FA
 CN 400JB9103-88
 CN A 1760
 CN Adeka Fatty Acid SA 910

Search done by Noble Jarrell

CN Barolub FTA
CN Century 1210
CN Century 1220
CN Century 1230
CN Century 1240
CN Edenor C 18/98
CN Edenor C18
CN Edenor HT-JG 60
CN Edenor ST 1
CN Edenor ST 20
CN Emersol 120
CN Emersol 153NF
CN Emersol 6349
CN F 3
CN F 3 (lubricant)
CN FA 1655
CN G 270
CN Humko Industrene R
CN Hydrofol Acid 150
CN Hydrofol Acid 1895
CN Hystrene 5016
CN Hystrene 80
CN Hystrene 9718
CN Hystrene 9718NF
CN Hystrene 9718NFFG
CN Hystrene S 97
CN Hystrene T 70
CN Industrene 5016K
CN Industrene 8718
CN Industrene 9018
CN Industrene R
CN Kam 1000
CN Kam 2000
CN Kam 3000
CN Kortacid 1895
CN Loxiol G 20
CN Lunac 30
CN Lunac S 20
CN Lunac S 30
CN Lunac S 40
CN Lunac S 50
CN Lunac S 90
CN Lunac S 90KC
CN Lunac S 98
CN Lunac YA

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS 3D CONCORD

DR 8013-28-3, 8023-06-1, 8037-40-9, 8037-83-0, 8039-51-8, 8039-52-9,
8039-53-0, 8039-54-1, 58392-66-8, 134503-33-6, 82497-27-6, 39390-61-9,
197923-10-7, 294203-07-9

MF C18 H36 O2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB,
DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2,
ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*,
PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USAN,
USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**


(**Enter CHEMLIST File for up-to-date regulatory information)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

46455 REFERENCES IN FILE CA (1907 TO DATE)
3448 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
46520 REFERENCES IN FILE CAPLUS (1907 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2005 ACS on STN
RN 57-10-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Hexadecanoic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Palmitic acid (7CI, 8CI)
OTHER NAMES:
CN 1-Pentadecanecarboxylic acid
CN Cetylic acid
CN Edenor C16
CN Emersol 143
CN FA 1695
CN Hydrofol Acid 1690
CN Hystrene 9016
CN Kortacid 1698
CN Loxiol EP 278
CN Lunac P 95
CN Lunac P 95KC
CN Lunac P 98
CN n-Hexadecanoic acid
CN n-Hexadecoic acid
CN NAA 160
CN Neo-Fat 16
CN NSC 5030
CN PA 900
CN Palmitinic acid
CN Pentadecanecarboxylic acid
CN Prifac 2960
CN Pristerene 4934
FS 3D CONCORD
DR 60605-23-4, 66321-94-6, 116860-99-2, 212625-86-0
MF C16 H32 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DETERM*, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT,
ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PIRA,
PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN,
USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

38879 REFERENCES IN FILE CA (1907 TO DATE)
1506 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
38940 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> b wpix

FILE 'WPIX' ENTERED AT 07:55:37 ON 10 JUN 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 8 JUN 2005 <20050608/UP>
 MOST RECENT DERWENT UPDATE: 200536 <200536/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
 PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
 FOR DETAILS. <<<

=> d iall 18 tot

L8 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2003-812476 [76] WPIX
 DOC. NO. CPI: C2003-225898
 TITLE: Regulating the level of a fatty acid in a system, useful
 for treating cardiovascular, neurological or
 developmental disorders, comprises regulating the
 phosphatidylethanolamine-N-methyltransferase (PEMT)
 activity in the system.
 DERWENT CLASS: B04 D16
 INVENTOR(S): BAILLIE, R A; WATKINS, S M
 PATENT ASSIGNEE(S): (BAIL-I) BAILLIE R A; (WATK-I) WATKINS S M; (LIPO-N)
 LIPOMICS TECHNOLOGIES INC
 COUNTRY COUNT: 103
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN	IPC
WO 2003078574	A2	20030925	(200376)*	EN	60	C12N000-00	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS							
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW							
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK							
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR							
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT							
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA							
ZM ZW							
US 2004024065	A1	20040205	(200411)			A61K031-202	
AU 2003225726	A1	20030929	(200432)			C12N000-00	
EP 1490076	A2	20041229	(200502)	EN		A61K035-12	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV							
MC MK NL PT RO SE SI SK TR							

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003078574	A2	WO 2003-US7242	20030307
US 2004024065	A1 Provisional	US 2002-363587P	20020311 <--
	Provisional	US 2002-373912P	20020419 <--
	Provisional	US 2002-401684P	20020806 <--
	Provisional	US 2002-424949P	20021108 <--
	Provisional	US 2002-436192P	20021224 <--
		US 2003-383850	20030307
AU 2003225726	A1	AU 2003-225726	20030307
EP 1490076	A2	EP 2003-744631	20030307
		WO 2003-US7242	20030307

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003225726	A1 Based on	WO 2003078574
EP 1490076	A2 Based on	WO 2003078574

PRIORITY APPLN. INFO: US 2002-436192P
 20021224; US
 2002-363587P 20020311;
 US 2002-373912P
 20020419; US
 2002-401684P 20020806;
 US 2002-424949P
 20021108; US 2003-383850
 20030307

INT. PATENT CLASSIF.:

MAIN: A61K031-202; A61K035-12; C12N000-00

SECONDARY: A61K031-07; A61K031-20; A61K031-685

BASIC ABSTRACT:

WO2003078574 A UPAB: 20031125

NOVELTY - Regulating the level of a fatty acid in a system comprising regulating the phosphatidylethanolamine-N-methyltransferase (PEMT) activity in the system to regulate the level of a fatty acid in the system, where the fatty acid is selected from 16:0, 18:0, 16:1n7, 18:1n7, 18:2n6, 20:4n6, 20:5n3, 22:6n3, saturated fatty acids, polyunsaturated fatty acids, and highly unsaturated fatty acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) decreasing the level of a fatty acid in a system;
- (2) increasing the PEMT activity in a subject;
- (3) regulating a lipoprotein component ratio in a system;
- (4) regulating the density or size of a lipoprotein in a system;
- (5) assessing the density or size of a lipoprotein in a system;
- (6) treating or preventing a cardiovascular or neurological condition, or a condition associated with PEMT activity;
- (7) assessing the susceptibility of a subject to a cardiovascular or developmental condition;
- (8) assessing the susceptibility of a subject to the toxicity of an agent;
- (9) assessing the susceptibility of a subject to a condition associated with infertility;
- (10) assessing the exposure of a subject to an agent in an environment;
- (11) assessing a condition in a subject;
- (12) predicting effectiveness of an agent for treating neoplasia;
- (13) increasing milk production in a subject;
- (14) increasing the lipid or phospholipid content of milk in a subject; and
- (15) preventing a birth defect of a subject.

ACTIVITY - Cardiant; Antiartherosclerotic; Antilipemic; Nootropic; Neuroprotective; Dermatological; Antiinflammatory; Cytostatic; Hepatotrophic; Anorectic; Immunosuppressive; Antirheumatic; Antiarthritic. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The methods and agents are useful for preventing or treating a cardiovascular condition, e.g. atherosclerosis, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hypertension, hyperglycemia, stroke, ischemic heart diseases, cardiomyopathy, arrhythmia, coronary artery diseases, and heart attack; a neurological condition, e.g. neurodevelopment or neurodegeneration of the subject, Asperger's Syndrome, Attention Deficit Hyperactivity Disorder, Autism spectrum disorder, Cerebral Palsy, Dysthymic Disorder, Fragile X Syndrome, Perinatally Acquired HIV Disease, Tourette's Syndrome, Alternating Hemiplegia of Childhood, Congenital Anomalies, Amold-Chiari Malformation, Meningocele, Spina Bifida, Dandy Walker Syndrome, vascular malformations, Holoprosencephaly, and Hydranencephaly, Alpers' disease, Alzheimer's Disease, Autosomal Dominant Neurodegenerative Disorder, Batten Disease, Cerebral calcinosis, Cockayne Syndrome, corticobasal, ganglionic degeneration, Dementia with Lewy Bodies, Lewy Body Variant, Alzheimer's Disease, Motor Neuron Disease, Multiple System Atrophy, Parkinson Plus syndrome, Neuronal intranuclear inclusion disease, Olivopontocerebellar Atrophy, Parkinsonian Syndromes, Pick's disease, Postpoliomyelitis Syndrome, Progressive Supranuclear Palsy, Rett Syndrome, Shy-Drager Syndrome, Tauopathies, Tri-nucleotide repeat diseases, and Tuberous Sclerosis; a developmental disorder, e.g. birth defects, congenital developmental conditions, Microcephaly and mental retardation of uncontrolled phenylketonuria (PKU); or a condition associated with the PEMT activity, e.g. cirrhosis, skin disorders, neoplasia, infectious diseases, inflammatory diseases, bone density, eicosanoid production, osteoporosis, insulin sensitivity or resistance, diabetes, obesity, renal function loss, autoimmune diseases, and atopic diseases, lipid accumulation in liver, liver steatosis, complications associated with liver transplantation, growth hormone deficiency or overproduction, thyroid hormone disorders, skin disorders, infectious diseases, rheumatoid arthritis, osteoporosis, atopic diseases, cirrhosis, renal functional loss, autoimmune diseases, lipid accumulation in liver, complications associated with liver transplantation, insulin resistance, growth hormone deficiency or excess, insulin resistance, neoplasia, or chronic bowel inflammation (all claimed).

Dwg.0/20

FILE SEGMENT:	CPI
FIELD AVAILABILITY:	AB
MANUAL CODES:	CPI: B11-C08E; B12-K04A; B12-K04E; B14-C03; B14-E12; B14-F01A; B14-F01B; B14-F02B; B14-F02D; B14-F07; B14-F09; B14-G02D; B14-H01; B14-J01A3; B14-J01A4; B14-J01B3; B14-N01; B14-N10; B14-N11; B14-N12; B14-N16; B14-N17; B14-S04; D05-H09

=> b home

FILE 'HOME' ENTERED AT 07:55:42 ON 10 JUN 2005.

=>

=> d his full

(FILE 'HOME' ENTERED AT 07:50:20 ON 10 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 07:50:59 ON 10 JUN 2005

E WATKINS S/AU
 L1 26 SEA ABB=ON PLU=ON ("WATKINS S"/AU OR "WATKINS S M"/AU)
 E WATKINS STEVEN/AU
 L2 24 SEA ABB=ON PLU=ON ("WATKINS STEVEN"/AU OR "WATKINS STEVEN
 M"/AU OR "WATKINS STEVEN MICHAEL"/AU)
 E WATKINS STEPHEN/AU
 L3 10 SEA ABB=ON PLU=ON ("WATKINS STEPHEN"/AU OR "WATKINS STEVE"/AU
)
 L4 12 SEA ABB=ON PLU=ON LIPOMICS/CS, PA
 L5 1 SEA ABB=ON PLU=ON (US2002-436192# OR US2002-424949# OR
 US2002-401684# OR US2002-373912# OR US2002-363587#)/AP, PRN

FILE 'REGISTRY' ENTERED AT 07:54:30 ON 10 JUN 2005

FILE 'HCAPLUS' ENTERED AT 07:54:32 ON 10 JUN 2005

L6 TRA L5 1- RN : 20 TERMS

FILE 'REGISTRY' ENTERED AT 07:54:32 ON 10 JUN 2005

L7 20 SEA ABB=ON PLU=ON L6

FILE 'WPIX' ENTERED AT 07:54:36 ON 10 JUN 2005

L8 1 SEA ABB=ON PLU=ON (US2002-436192# OR US2002-424949# OR
 US2002-401684# OR US2002-373912# OR US2002-363587#)/AP, PRN

FILE 'MEDLINE' ENTERED AT 08:18:11 ON 10 JUN 2005

E WATKINS S/AU
 L9 181 SEA ABB=ON PLU=ON ("WATKINS S"/AU OR "WATKINS S M"/AU)
 E WATKINS STEVE/AU
 L10 11 SEA ABB=ON PLU=ON ("WATKINS STEVE"/AU OR "WATKINS STEVEN
 M"/AU)
 L11 7 SEA ABB=ON PLU=ON LIPOMICS/CS
 L12 24 SEA ABB=ON PLU=ON (L9 OR L10 OR L11) AND LIPIDS+NT/CT
 L13 227698 SEA ABB=ON PLU=ON LIPIDS+NT/CT (L) (BI OR ME)/CT
 L14 11 SEA ABB=ON PLU=ON L13 AND L12
 L15 46750 SEA ABB=ON PLU=ON LIPIDS+NT/CT (L) BI/CT
 L16 1 SEA ABB=ON PLU=ON L15 AND (L9 OR L10 OR L11)
 L17 227687 SEA ABB=ON PLU=ON L13 NOT L14
 L18 6024 SEA ABB=ON PLU=ON L17 AND (BIOLOGICAL MARKERS+NT OR GENETIC
 MARKERS+NT)/CT
 L19 25741 SEA ABB=ON PLU=ON L15/MAJ
 L20 302326 SEA ABB=ON PLU=ON (BIOLOGICAL MARKERS+NT OR GENETIC MARKERS+N
 T)/CT
 L21 124975 SEA ABB=ON PLU=ON L20/MAJ
 L22 203 SEA ABB=ON PLU=ON L19 AND L21
 L23 192 SEA ABB=ON PLU=ON L22 AND PY<=2003
 L24 60952 SEA ABB=ON PLU=ON L21 (L) (AN OR CH OR ME)/CT
 L25 61 SEA ABB=ON PLU=ON L23 AND L24
 L26 QUE ABB=ON PLU=ON (DIAGNOSTIC TECHNIQUES, RADIOISOTOPE+NT OR
 ISOTOPE LABELING +NT OR ISOTOPES+NT)/CT,
 L27 22542 SEA ABB=ON PLU=ON L17 AND L26
 L28 430472 SEA ABB=ON PLU=ON (DIAGNOSTIC TECHNIQUES, RADIOISOTOPE+NT OR
 ISOTOPE LABELING +NT OR ISOTOPES+NT)/CT
 L29 116390 SEA ABB=ON PLU=ON L28/MAJ
 L30 501 SEA ABB=ON PLU=ON L29 AND L13/MAJ
 L31 463 SEA ABB=ON PLU=ON L30 AND PY<=2002
 L32 182 SEA ABB=ON PLU=ON L22 AND PY<=2002
 L33 59 SEA ABB=ON PLU=ON L32 AND L24
 SEL AN 4 10 18 29 38-39 44-45 55 57-59 L33
 L34 12 SEA ABB=ON PLU=ON (2000125582/AN OR 2001439982/AN OR
 2002196758/AN OR 83213694/AN OR 86282150/AN OR 87274197/AN OR
 88253285/AN OR 94294385/AN OR 95180311/AN OR 96149161/AN OR

```

          96185017/AN OR 97450953/AN) AND L33
          SEL AN 8 L34
L35      1 SEA ABB=ON PLU=ON 94294385/AN AND L34
L36     184 SEA ABB=ON PLU=ON ISOTOPE LABELING +NT/CT AND L15
L37    10821 SEA ABB=ON PLU=ON ISOTOPE LABELING +NT/CT
L38     2114 SEA ABB=ON PLU=ON L37/MAJ
L39      7 SEA ABB=ON PLU=ON L38 AND L15
L40      6 SEA ABB=ON PLU=ON L39 AND PY<=2002
L41    28806 SEA ABB=ON PLU=ON (CYTIDINE DIPHOSPHATE CHOLINE+NT OR
          PHOSPHOLIPASES+NT OR STEROL O-ACYLTRANSFERASE OR GLYCEROL-3-PHO
          SPHATE O-ACYLTRANSFERASE+NT)/CT
L42    15879 SEA ABB=ON PLU=ON L41/MAJ
L43     5606 SEA ABB=ON PLU=ON L42 AND L13
L44   122676 SEA ABB=ON PLU=ON L13/MAJ
L45     2815 SEA ABB=ON PLU=ON L44 AND L42
L46      60 SEA ABB=ON PLU=ON L45 AND (L20 OR L37)
L47      54 SEA ABB=ON PLU=ON L46 AND PY<=2002
L48      9 SEA ABB=ON PLU=ON L19 AND L42 AND (L20 OR L37)
L49     59 SEA ABB=ON PLU=ON L29 AND L19
L50      1 SEA ABB=ON PLU=ON L49 AND (L41 OR L42)
L51     56 SEA ABB=ON PLU=ON L49 AND PY<=2002
          SEL AN 46-56 37-42 34-36 29-30 24-25 27 17-21 15 5-12 2 L51
L52     40 SEA ABB=ON PLU=ON (1998272311/AN OR 1998382434/AN OR
          2000029087/AN OR 2000029095/AN OR 2000481149/AN OR 66071506/AN
          OR 66157647/AN OR 67003285/AN OR 67004390/AN OR 67061525/AN OR
          67126401/AN OR 67160888/AN OR 67179526/AN OR 67202029/AN OR
          67216680/AN OR 68157948/AN OR 71090573/AN OR 71288112/AN OR
          72098476/AN OR 73145444/AN OR 74062356/AN OR 77109534/AN OR
          77164650/AN OR 77176576/AN OR 77215888/AN OR 81175008/AN OR
          83100402/AN OR 85258111/AN OR 86104369/AN OR 87148087/AN OR
          90234177/AN OR 90345294/AN OR 91182817/AN OR 92044100/AN OR
          93035907/AN OR 93152551/AN OR 94358640/AN OR 96292203/AN OR
          97091885/AN OR 97161767/AN) AND L51
L53     43 SEA ABB=ON PLU=ON L52 OR L40 OR L35
L54      0 SEA ABB=ON PLU=ON L53 AND (L9 OR L10 OR L11)
          SEL AN L53 26-43 20-24 11-13 15 18 1-9
L55     37 SEA ABB=ON PLU=ON (1998272311/AN OR 1998382434/AN OR
          2000029087/AN OR 2000029095/AN OR 2000481149/AN OR 66071506/AN
          OR 66157647/AN OR 67003285/AN OR 67004390/AN OR 67061525/AN OR
          67126401/AN OR 67160888/AN OR 67179526/AN OR 67202029/AN OR
          67216680/AN OR 68157948/AN OR 71090573/AN OR 71288112/AN OR
          72098476/AN OR 73145444/AN OR 73216685/AN OR 74062356/AN OR
          77109534/AN OR 77176576/AN OR 77215888/AN OR 81175008/AN OR
          83100402/AN OR 85258111/AN OR 86104369/AN OR 90345294/AN OR
          92044100/AN OR 93035907/AN OR 93152551/AN OR 94358640/AN OR
          96292203/AN OR 97091885/AN OR 97161767/AN) AND L53

```

=> b medl

FILE 'MEDLINE' ENTERED AT 11:15:32 ON 10 JUN 2005

FILE LAST UPDATED: 9 JUN 2005 (20050609/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

Search done by Noble Jarrell

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l14 tot

L14 ANSWER 1 OF 11 MEDLINE on STN
 AN 2004128525 MEDLINE
 DN PubMed ID: 14668353
 TI Lipopenia and skin barrier abnormalities in DGAT2-deficient mice.
 AU Stone Scot J; Myers Heather M; Watkins Steven M; Brown Barbara E; Feingold Kenneth R; Elias Peter M; Farese Robert V Jr
 CS Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-1900, USA.
 NC DK56084 (NIDDK)
 SO Journal of biological chemistry, (2004 Mar 19) 279 (12) 11767-76.
 Electronic Publication: 2003-12-10.
 Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 20040316
 Last Updated on STN: 20040528
 Entered Medline: 20040527
 AB The synthesis of triglycerides is catalyzed by two known acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes. Although they catalyze the same biochemical reaction, these enzymes share no sequence homology, and their relative functions are poorly understood. Gene knockout studies in mice have revealed that DGAT1 contributes to triglyceride synthesis in tissues and plays an important role in regulating energy metabolism but is not essential for life. Here we show that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival. DGAT2-deficient (Dgat2(-/-)) mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin. DGAT1 was unable to compensate for the absence of DGAT2, supporting the hypothesis that the two enzymes play fundamentally different roles in mammalian triglyceride metabolism.
 CT Acyltransferases: GE, genetics
 *Acyltransferases: PH, physiology
 Amino Acid Sequence
 Animals
 Base Sequence
 Cell Line, Tumor
 DNA Primers
 Homeostasis
 Mice
 Rats
 Research Support, Non-U.S. Gov't
 Research Support, U.S. Gov't, P.H.S.
 *Skin Abnormalities: GE, genetics
 Triglycerides: BI, biosynthesis
 *Triglycerides: ME, metabolism
 CN 0 (DNA Primers); 0 (Triglycerides); EC 2.3. (Acyltransferases); EC 2.3.1.20 (diacylglycerol O-acyltransferase)

L14 ANSWER 2 OF 11 MEDLINE on STN
 AN 2004100027 MEDLINE
 DN PubMed ID: 14991909
 TI Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on fatty acid availability and neural tube formation in cynomolgus macaque, Macaca fascicularis.
 AU Moran F M; Hendrickx A G; Shideler S; Overstreet J W; Watkins S M
 ; Lasley B L
 CS Center for Health and the Environment, University of California, Davis,

Search done by Noble Jarrell

California 95616, USA.

SO Birth defects research. Part B, Developmental and reproductive toxicology, (2004 Feb) 71 (1) 37-46.
Journal code: 101155115. ISSN: 1542-9733.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200409

ED Entered STN: 20040302
Last Updated on STN: 20040929
Entered Medline: 20040928

AB 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is known to alter carbohydrate utilization and specific steps in lipid metabolism. TCDD interacts with estradiol in mobilizing specific fatty acids in chickens that may be a cause of cranial/beak malformations in this species. This study was designed to test the hypothesis that TCDD simultaneously alters critical fatty acid mobilization during early pregnancy and determine if those changes correlate to morphological defects of the developing neural tube in the nonhuman primate. Cynomolgus macaques were treated with a single dose of 4 microg/kg body weight (BW) TCDD on gestational day 15 or 20. Pregnancies were terminated by hysterectomy on gestational day 24-26 and embryos were examined to determine morphology of the developing neural tube. Maternal blood samples were used for fatty acid quantification. Embryos exhibited cellular changes, mainly increased cell death, and intercellular spaces in the neural tube, suggestive of an adverse effect on the developing nervous system. Significant decreases on fatty acid composition were found on some of the eight classes of lipids analyzed. Particularly, a decrease was observed in the n-3 (40-60%) and n-6 (47-75%) essential fatty acids in treated pregnancies compared to untreated controls. These data demonstrate the effect of TCDD in decreasing maternal levels of n-3 and n-6 fatty acids that are considered necessary for normal development in mammals. Since neural tube development is dependent, in part, on n-3 and n-6 fatty acids, it is possible that the limitation of these essential fatty acids in plasma resulted in the observed detrimental effects on early brain development.
Copyright 2004 Wiley-Liss, Inc.

CT Check Tags: Female
Animals
Brain: PA, pathology
Embryo: DE, drug effects
Embryo: PA, pathology
Fatty Acids: AN, analysis
*Fatty Acids: ME, metabolism
Lipid Mobilization: DE, drug effects
Lipids: BL, blood
Lipids: CH, chemistry
Macaca fascicularis
*Neural Tube Defects: CI, chemically induced
Neural Tube Defects: PA, pathology
Pregnancy
Tetrachlorodibenzodioxin: PD, pharmacology
*Tetrachlorodibenzodioxin: TO, toxicity

RN 1746-01-6 (Tetrachlorodibenzodioxin)

CN 0 (Fatty Acids); 0 (Lipids)

L14 ANSWER 3 OF 11 MEDLINE on STN

AN 2004092462 MEDLINE

DN PubMed ID: 14982154

TI Lipomic profiling in drug discovery, development and clinical trial evaluation.

AU Watkins Steven M

CS Lipomics Technologies Inc., 2545 Boatman Avenue, West
Sacramento, CA 95691, USA.. steve.watkins@lipomics.com

SO Current opinion in drug discovery & development, (2004 Jan) 7 (1) 112-7.
Ref: 27

Journal code: 100887519. ISSN: 1367-6733.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 200406

ED Entered STN: 20040302
Last Updated on STN: 20040615
Entered Medline: 20040614

AB Dysregulation of lipid metabolism plays a crucial role in the progression of many diseases and in adverse drug response. Changes in lipid metabolism leading to disease are often not detected using biomarker analyses because these changes are defined by a subtle, long-term shift in the concentrations of many metabolites simultaneously. The application of the principals of 'omics to the study of lipids, which include the development of comprehensive, high-throughput assays and centralized reference databases, is beginning to produce an integrated and actionable knowledge of lipids and their relationship to pathology. These analytical tools and the assembled knowledge will enable the discovery, development and testing of drugs to be conducted with a deeper knowledge of their effects on lipid metabolism.

CT Animals
Chromatography, Gas
Chromatography, High Pressure Liquid
Clinical Trials
Databases, Factual
*Drug Design
Humans
 *Lipids: CH, chemistry
 *Lipids: ME, metabolism
Magnetic Resonance Spectroscopy
Pharmaceutical Preparations: AE, adverse effects
Pharmaceutical Preparations: CH, chemistry
 Phospholipids: CH, chemistry
 Phospholipids: ME, metabolism
Spectrum Analysis, Mass
 Triglycerides: CH, chemistry
 Triglycerides: ME, metabolism

CN 0 (Lipids); 0 (Pharmaceutical Preparations); 0 (Phospholipids); 0 (Triglycerides)

L14 ANSWER 4 OF 11 MEDLINE on STN

AN 2003530359 MEDLINE

DN PubMed ID: 14608048

TI Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice.

AU Watkins Steven M; Zhu Xiaonan; Zeisel Steven H

CS Lipomics Technologies, Incorporated, West Sacramento, CA 95691, USA.. steve.watkins@lipomics.com

NC AG09525 (NIA)
DK55865 (NIDDK)
DK56350 (NIDDK)
ES10126 (NIEHS)

SO Journal of nutrition, (2003 Nov) 133 (11) 3386-91.
Journal code: 0404243. ISSN: 0022-3166.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200408

ED Entered STN: 20031111
Last Updated on STN: 20040825
Entered Medline: 20040824

AB Phosphatidylethanolamine-N-methyltransferase (PEMT) catalyzes the methylation of phosphatidylethanolamine to form phosphatidylcholine (PC) and represents one of the two major pathways for PC biosynthesis. Mice with a homozygous disruption of the PEMT gene are dependent on the 1,2-diacylglycerol cholinephosphotransferase (CDP-choline) pathway for the synthesis of PC and develop severe liver steatosis when fed a diet deficient in choline. The present study used quantitative lipid metabolite profiling to characterize lipid metabolism in PEMT-deficient mice fed diets containing varying concentrations of choline. Choline supplementation restored liver, but not plasma PC concentrations of PEMT-deficient mice to levels commensurate with control mice. Choline supplementation also restored plasma triglyceride concentrations to normal levels, but did not restore plasma cholesterol ester concentrations in the PEMT-deficient mice to those equal to control mice. PEMT-deficient mice also had substantially diminished concentrations of docosahexaenoic acid [22:6(n-3)] and arachidonic acid [20:4(n-6)] in plasma, independent of choline status. Thus, choline supplementation rescued some but not all of the phenotypes induced by the knockout. These findings indicate that PEMT activity functions beyond its recognized role as a compensatory pathway for PC biosynthesis and that, in contrast, PEMT activity is involved in many physiologic processes including the flux of lipid between liver and plasma and the delivery of essential fatty acids to blood and peripheral tissues via the liver-derived lipoproteins.

CT Animals

Cholesterol Esters: ME, metabolism

Choline: AD, administration & dosage

*Choline: PD, pharmacology

Diet

*Fatty Acids, Essential: ME, metabolism

Lipids: BL, blood

*Lipids: ME, metabolism

Liver: DE, drug effects

*Liver: ME, metabolism

*Methyltransferases: DF, deficiency

Methyltransferases: GE, genetics

*Methyltransferases: ME, metabolism

Mice

Mice, Knockout

Phospholipids: ME, metabolism

Research Support, U.S. Gov't, P.H.S.

Triglycerides: ME, metabolism

RN 62-49-7 (Choline)

CN 0 (Cholesterol Esters); 0 (Fatty Acids, Essential); 0 (Lipids); 0 (Phospholipids); 0 (Triglycerides); EC 2.1.1. (Methyltransferases); EC 2.1.1.17 (Phosphatidylethanolamine N-methyltransferase)

L14 ANSWER 5 OF 11 MEDLINE on STN

AN 2002642802 MEDLINE

DN PubMed ID: 12401879

TI Lipid metabolome-wide effects of the PPARGgamma agonist rosiglitazone.

AU Watkins Steven M; Reifsnnyder Peter R; Pan Huei-ju; German J Bruce; Leiter Edward H

CS Lipomics Technologies, Inc, 2545 Boatman Ave, West Sacramento, CA 95691, USA.. steve.watkins@lipomics.com

NC CA-34196 (NCI)

DK56853 (NIDDK)

SO Journal of lipid research, (2002 Nov) 43 (11) 1809-17.

Journal code: 0376606. ISSN: 0022-2275.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200309

ED Entered STN: 20021029

Last Updated on STN: 20030903

Entered Medline: 20030902

AB Successful therapy for chronic diseases must normalize a targeted aspect of metabolism without disrupting the regulation of other metabolic pathways essential for maintaining health. Use of a limited number of single molecule surrogates for disease, or biomarkers, to monitor the efficacy of a therapy may fail to predict undesirable side effects. In this study, a comprehensive metabolomic assessment of lipid metabolites was employed to determine the specific effects of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone on structural lipid metabolism in a new mouse model of Type 2 diabetes. Dietary supplementation with rosiglitazone (200 mg/kg diet) suppressed Type 2 diabetes in obese (NZO x NON)F1 male mice, but chronic treatment markedly exacerbated hepatic steatosis. The metabolomic data revealed that rosiglitazone i) induced hypolipidemia (by dysregulating liver-plasma lipid exchange), ii) induced de novo fatty acid synthesis, iii) decreased the biosynthesis of lipids within the peroxisome, iv) substantially altered free fatty acid and cardiolipin metabolism in heart, and v) elicited an unusual accumulation of polyunsaturated fatty acids within adipose tissue. These observations suggest that the phenotypes induced by rosiglitazone are mediated by multiple tissue-specific metabolic variables. Because many of the effects of rosiglitazone on tissue metabolism were reflected in the plasma lipid metabolome, metabolomics has excellent potential for developing clinical assessments of metabolic response to drug therapy.

CT Check Tags: Male
 Adipose Tissue: DE, drug effects
 Adipose Tissue: ME, metabolism
 Animals
 Diabetes Mellitus, Type 2: ME, metabolism
 Gene Expression: DE, drug effects
 Heart: DE, drug effects
 Lipids: BL, blood
 *Lipids: ME, metabolism
 Liver: DE, drug effects
 Liver: ME, metabolism
 Mice
 Mice, Obese
 Myocardium: ME, metabolism
 *Receptors, Cytoplasmic and Nuclear: AG, agonists
 Research Support, Non-U.S. Gov't
 Research Support, U.S. Gov't, P.H.S.
 *Thiazoles: PD, pharmacology
 *Thiazolidinediones
 *Transcription Factors: AG, agonists
 Weight Gain
 RN 122320-73-4 (rosiglitazone)
 CN 0 (Lipids); 0 (Receptors, Cytoplasmic and Nuclear); 0 (Thiazoles); 0 (Thiazolidinediones); 0 (Transcription Factors)

L14 ANSWER 6 OF 11 MEDLINE on STN
 AN 2002390456 MEDLINE
 DN PubMed ID: 12139307
 TI Metabolomics and biochemical profiling in drug discovery and development.
 AU Watkins Steven M; German J Bruce
 CS Lipomics Technologies Inc, West Sacramento, CA 95691, USA..
 steve.watkins@lipomics.com
 SO Current opinion in molecular therapeutics, (2002 Jun) 4 (3) 224-8. Ref:
 21
 Journal code: 100891485. ISSN: 1464-8431.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 20020726

Last Updated on STN: 20030110

Entered Medline: 20030109

AB Metabolomics brings a different and complementary perspective to biomedical research and therapeutic development. Metabolites are measurable, directly responsible for health, and changeable through intervention. By definition, the concentrations of metabolites are the direct reflection of metabolism, and by measuring changes in metabolite concentrations, the full range of biochemical effects induced by a therapeutic intervention can be determined. In a clinical setting, metabolomics can be used to diagnose or predict disease, stratify patient populations by their specific metabolism, or to determine the safety or efficacy of a therapeutic intervention. Metabolomics is useful in virtually all aspects of biomedical research, and it is likely to evolve into an essential component of the drug discovery and development process.

CT Animals

*Drug Design

Gene Expression Profiling

*Genomics

Humans

Lipids: AN, analysis

Lipids: CL, classification

Lipids: ME, metabolism

Magnetic Resonance Spectroscopy

*Metabolism

Metabolism, Inborn Errors: DI, diagnosis

Metabolism, Inborn Errors: GE, genetics

Metabolism, Inborn Errors: ME, metabolism

Pharmaceutical Preparations: AN, analysis

Pharmaceutical Preparations: ME, metabolism

Pharmacogenetics

CN 0 (Lipids); 0 (Pharmaceutical Preparations)

L14 ANSWER 7 OF 11 MEDLINE on STN

AN 2002016566 MEDLINE

DN PubMed ID: 11423386

TI Interaction of estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with hepatic fatty acid synthesis and metabolism of male chickens (Gallus domesticus).

AU Stanton B; Watkins S; German J B; Lasley B

CS Institute of Toxicology and Environmental Health (ITEH), University of California Davis, One Shields Ave., 95616, Davis, CA, USA..
rjstanton@ucdavis.edu

SO Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, (2001 Jun) 129 (2) 137-50.

Journal code: 100959500. ISSN: 1532-0456.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200112

ED Entered STN: 20020121

Last Updated on STN: 20020121

Entered Medline: 20011204

AB This study tested the hypothesis that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) antagonizes estrogen-induced hepatic lipid synthesis and metabolism in birds. Twenty immature male chickens (Gallus domesticus) were divided evenly into four groups: (1) vehicle control; (2) estrogen alone (1.0 mg/kg estradiol cypionate injected on three consecutive days); (3) TCDD alone (50 microg/kg injected on the fourth day); and (4) a combination of the estrogen and TCDD treatments. On day 14, liver samples were collected for quantitative fatty acid analysis by capillary gas chromatography. Birds treated with estrogen alone had increased total triacylglyceride concentrations with specific increases in the Delta9 desaturase products 16:1n7, 18:1n7, 18:1n9, and 20:1n9. In addition, estrogen treatment specifically increased 22:6n3 concentrations in both triacylglycerides and phospholipids. However, these increases in Delta9 desaturase products or

22:6n3 did not occur for birds treated with estrogen in combination with TCDD. TCDD and estrogen plus TCDD treatments increased phospholipid concentrations of the diet-derived polyunsaturated fatty acids 18:2n6, 18:3n6, 20:3n6, 18:3n3, and 20:5n3, although only the estrogen plus TCDD group had significantly increased total phospholipids. In cholesterol esters, all three treatments decreased concentrations of total fatty acids, saturated fatty acids, and Delta9 desaturase products compared to the control group.

CT Check Tags: Male

Animals

*Chickens: ME, metabolism

Chromatography, Gas

Chromatography, Thin Layer

Dose-Response Relationship, Drug

Drug Antagonism

*Environmental Pollutants: PD, pharmacology

*Estrogen Antagonists: PD, pharmacology

*Fatty Acids: ME, metabolism

Liver: DE, drug effects

*Liver: ME, metabolism

Phospholipids: ME, metabolism

Research Support, Non-U.S. Gov't

Research Support, U.S. Gov't, Non-P.H.S.

Tetrachlorodibenzodioxin: ME, metabolism

*Tetrachlorodibenzodioxin: PD, pharmacology

Triglycerides: ME, metabolism

Wasting Syndrome: CI, chemically induced

Wasting Syndrome: VE, veterinary

RN 1746-01-6 (Tetrachlorodibenzodioxin)

CN 0 (Environmental Pollutants); 0 (Estrogen Antagonists); 0 (Fatty Acids); 0 (Phospholipids); 0 (Triglycerides)

L14 ANSWER 8 OF 11 MEDLINE on STN

AN 2001691991 MEDLINE

DN PubMed ID: 11739435

TI Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes.

AU Goodpaster B H; He J; Watkins S; Kelley D E

CS Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.. bgood+@pitt.edu

NC 1P30DK46204 (NIDDK)

5M01RR00056 (NCRR)

K01 AG00851 (NIA)

R01 DK-49200-04 (NIDDK)

SO Journal of clinical endocrinology and metabolism, (2001 Dec) 86 (12) 5755-61.

Journal code: 0375362. ISSN: 0021-972X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200112

ED Entered STN: 20011213

Last Updated on STN: 20020124

Entered Medline: 20011228

AB We examined the hypothesis that an excess accumulation of intramuscular lipid (IMCL) is associated with insulin resistance and that this may be mediated by the oxidative capacity of muscle. Nine sedentary lean (L) and 11 obese (O) subjects, 8 obese subjects with type 2 diabetes mellitus (D), and 9 lean, exercise-trained (T) subjects volunteered for this study. Insulin sensitivity (M) determined during a hyperinsulinemic (40 mU x m(-2)min(-1)) euglycemic clamp was greater (P < 0.01) in L and T, compared with O and D (9.45 +/- 0.59 and 10.26 +/- 0.78 vs. 5.51 +/- 0.61 and 1.15 +/- 0.83 mg x min(-1)kg fat free mass(-1), respectively). IMCL in percutaneous vastus lateralis biopsy specimens by quantitative image analysis of Oil Red O staining was approximately 2-fold higher in D than

in L (3.04 +/- 0.39 vs. 1.40 +/- 0.28% area as lipid; $P < 0.01$). IMCL was also higher in T (2.36 +/- 0.37), compared with L ($P < 0.01$). The oxidative capacity of muscle determined with succinate dehydrogenase staining of muscle fibers was higher in T, compared with L, O, and D (50.0 +/- 4.4, 36.1 +/- 4.4, 29.7 +/- 3.8, and 33.4 +/- 4.7 optical density units, respectively; $P < 0.01$). IMCL was negatively associated with M ($r = -0.57$, $P < 0.05$) when endurance-trained subjects were excluded from the analysis, and this association was independent of body mass index. However, the relationship between IMCL and M was not significant when trained individuals were included. There was a positive association between the oxidative capacity and M among nondiabetics ($r = 0.37$, $P < 0.05$). In summary, skeletal muscle of trained endurance athletes is markedly insulin sensitive and has a high oxidative capacity, despite having an elevated lipid content. In conclusion, the capacity for lipid oxidation may be an important mediator of the association between excess muscle lipid accumulation and insulin resistance.

CT Check Tags: Female; Male

Adult

Exercise

Humans

*Insulin Resistance

*Lipids: ME, metabolism

Middle Aged

*Muscle, Skeletal: ME, metabolism

Oxidation-Reduction

*Physical Education and Training

*Physical Endurance

Research Support, U.S. Gov't, P.H.S.

Succinate Dehydrogenase: ME, metabolism

CN 0 (Lipids); EC 1.3.99.1 (Succinate Dehydrogenase)

L14 ANSWER 9 OF 11 MEDLINE on STN

AN 2001504816 MEDLINE

DN PubMed ID: 11337979

TI Unique phospholipid metabolism in mouse heart in response to dietary docosahexaenoic or alpha-linolenic acids.

AU Watkins S M; Lin T Y; Davis R M; Ching J R; DePeters E J; Halpern G M; Walzem R L; German J B

CS Department of Food Science and Technology, 1 Shields Ave., University of California at Davis, Davis, CA 95616, USA.. smwatkins@ucdavis.edu

SO Lipids, (2001 Mar) 36 (3) 247-54.

Journal code: 0060450. ISSN: 0024-4201.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200109

ED Entered STN: 20010917

Last Updated on STN: 20010917

Entered Medline: 20010913

AB Diet and fatty acid metabolism interact in yet unknown ways to modulate membrane fatty acid composition and certain cellular functions. For example, dietary precursors or metabolic products of n-3 fatty acid metabolism differ in their ability to modify specific membrane components. In the present study, the effect of dietary 22:6n-3 or its metabolic precursor, 18:3n-3, on the selective accumulation of 22:6n-3 by heart was investigated. The mass and fatty acid compositions of individual phospholipids (PL) in heart and liver were quantified in mice fed either 22:6n-3 (from crocodile oil) or 18:3n-3 (from soybean oil) for 13 wk. This study was conducted to determine if the selective accumulation of 22:6n-3 in heart was due to the incorporation of 22:6n-3 into cardiolipin (CL), a PL most prevalent in heart and known to accumulate 22:6n-3. Although heart was significantly enriched with 22:6n-3 relative to liver, the accumulation of 22:6n-3 by CL in heart could not quantitatively account for this difference. CL from heart did accumulate 22:6n-3, but only in mice fed preformed 22:6n-3. Diets rich in non-22:6n-3 fatty acids

result in a fatty acid composition of phosphatidylcholine (PC) in heart that is unusually enriched with 22:6n-3. In this study, the mass of PC in heart was positively correlated with the enrichment of 22:6n-3 into PC. The increased mass of PC was coincident with a decrease in the mass of phosphatidylethanolamine, suggesting that 22:6n-3 induced PC synthesis by increasing phosphatidylethanolamine-N-methyltransferase activity in the heart.

CT Alligators and Crocodiles
Animals

Cardiolipins: ME, metabolism

*Dietary Fats, Unsaturated: PD, pharmacology

*Docosaehaenoic Acids: PD, pharmacology

Fatty Acids: AN, analysis

Lipids: AN, analysis

Liver: CH, chemistry

Liver: ME, metabolism

Mice

Myocardium: CH, chemistry

*Myocardium: ME, metabolism

Phosphatidylcholines: AN, analysis

Phosphatidylethanolamines: AN, analysis

Phospholipids: AN, analysis

*Phospholipids: ME, metabolism

Soybean Oil: PD, pharmacology

*alpha-Linolenic Acid: PD, pharmacology

RN 25167-62-8 (Docosaehaenoic Acids); 463-40-1 (alpha-Linolenic Acid);
8001-22-7 (Soybean Oil)

CN 0 (Cardiolipins); 0 (Dietary Fats, Unsaturated); 0 (Fatty Acids); 0
(Lipids); 0 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0
(Phospholipids)

L14 ANSWER 10 OF 11 MEDLINE on STN

AN 2001199367 MEDLINE

DN PubMed ID: 11289047

TI Skeletal muscle lipid content and oxidative enzyme activity in relation to
muscle fiber type in type 2 diabetes and obesity.

AU He J; Watkins S; Kelley D E

CS Department of Medicine, University of Pittsburgh School of Medicine,
Pennsylvania, USA.

NC 5 M01RR00056 (NCRR)

DK49200-06 (NIDDK)

P30DK462-08 (NIDDK)

SO Diabetes, (2001 Apr) 50 (4) 817-23.

Journal code: 0372763. ISSN: 0012-1797.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200104

ED Entered STN: 20010425

Last Updated on STN: 20010425

Entered Medline: 20010419

AB In obesity and type 2 diabetes, skeletal muscle has been observed to have a reduced oxidative enzyme activity, increased glycolytic activity, and increased lipid content. These metabolic characteristics are related to insulin resistance of skeletal muscle and are factors potentially related to muscle fiber type. The current study was undertaken to examine the interactions of muscle fiber type in relation to oxidative enzyme activity, glycolytic enzyme activity, and muscle lipid content in obese and type 2 diabetic subjects compared with lean healthy volunteers. The method of single-fiber analysis was used on vastus lateralis muscle obtained by percutaneous biopsy from 22 lean, 20 obese, and 20 type 2 diabetic subjects (ages 35+/-1, 42+/-2, and 52+/-2 years, respectively), with values for BMI that were similar in obese and diabetic subjects (23.7+/-0.7, 33.2+/-0.8, and 31.8+/-0.8 kg/m2, respectively). Oxidative enzyme activity followed the order of type I > type IIa > type IIb, but

within each fiber type, skeletal muscle from obese and type 2 diabetic subjects had lower oxidative enzyme activity than muscle from lean subjects ($P < 0.01$). Muscle lipid content followed a similar pattern in relation to fiber type, and within each fiber type, muscle from obese and type 2 diabetic subjects had greater lipid content ($P < 0.01$). In summary, based on single-fiber analysis, skeletal muscle in obese and type 2 diabetic subjects manifests disturbances of oxidative enzyme activity and increased lipid content that are independent of the effect of fiber type.

CT Check Tags: Female; Male

Adult

*Diabetes Mellitus, Type 2: ME, metabolism

Glycolysis

Humans

*Lipids: ME, metabolism

Middle Aged

Muscle Fibers, Fast-Twitch: ME, metabolism

Muscle Fibers, Slow-Twitch: ME, metabolism

*Muscle, Skeletal: ME, metabolism

*Obesity: ME, metabolism

*Oxidoreductases: ME, metabolism

Reference Values

Research Support, U.S. Gov't, Non-P.H.S.

Research Support, U.S. Gov't, P.H.S.

Thinness

CN 0 (Lipids); EC 1. (Oxidoreductases)

L14 ANSWER 11 OF 11 MEDLINE on STN

AN 1998381817 MEDLINE

DN PubMed ID: 9717717

TI Docosaehaenoic acid accumulates in cardiolipin and enhances HT-29 cell oxidant production.

AU Watkins S M; Carter L C; German J B

CS Department of Food Science and Technology, University of California, Davis 95616, USA.

NC 1 U24 AI37627 (NIAID)

SO Journal of lipid research, (1998 Aug) 39 (8) 1583-8.

Journal code: 0376606. ISSN: 0022-2275.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199811

ED Entered STN: 19990106

Last Updated on STN: 19990106

Entered Medline: 19981116

AB The objective of this study was to investigate membrane fatty acids for their effects on mitochondrial function in live cells. Mitochondrial potential and oxidant production were measured in human colonic adenocarcinoma (HT-29) cells with membranes enhanced in either oleic acid, linoleic acid, arachidonic acid, eicosapentaenoic acid, or docosaehaenoic acid. Docosaehaenoic acid-enriched cells had increased mitochondrial potential and produced 5-fold more cellular oxidants than did cells enriched with any other fatty acid. Oxidant production in fatty acid-enriched HT-29 cells did not correlate with the degree of unsaturation for total membrane fatty acids. However, there was a strong correlation between the degree of fatty acid unsaturation of cardiolipin, a critical inner-mitochondrial membrane phospholipid, and oxidant production. Cardiolipin acyl composition is known to influence the activity of electron transport complexes, an effect that can increase mitochondrial oxidant production. Docosaehaenoic acid was enriched to 48 mol% of the fatty acids present in HT-29 cell cardiolipin. These results demonstrate the importance of membrane acyl composition to mitochondrial potential and oxidant production in live cells. Additionally, results suggest that docosaehaenoic acid increases cell oxidant production by accumulating in cardiolipin, where its presence alters electron transport

efficiency.

CT Cardiolipins: CH, chemistry
 *Cardiolipins: ME, metabolism
 Cell Line
 *Docosaehaenoic Acids: ME, metabolism
 Electron Transport
 Fatty Acids: ME, metabolism
 Fatty Acids, Unsaturated: ME, metabolism
 Humans
 Membrane Lipids: CH, chemistry
 Membrane Lipids: ME, metabolism
 Membrane Potentials
 Mitochondria: ME, metabolism
 *Oxidants: ME, metabolism
 Phospholipids: CH, chemistry
 Phospholipids: ME, metabolism
 Reactive Oxygen Species: ME, metabolism
 Research Support, Non-U.S. Gov't
 Research Support, U.S. Gov't, P.H.S.
 RN 25167-62-8 (Docosaehaenoic Acids)
 CN 0 (Cardiolipins); 0 (Fatty Acids); 0 (Fatty Acids, Unsaturated); 0
 (Membrane Lipids); 0 (Oxidants); 0 (Phospholipids); 0 (Reactive Oxygen
 Species)

=> d all 155 tot

L55 ANSWER 1 OF 37 MEDLINE on STN
 AN 2000481149 MEDLINE
 DN PubMed ID: 10918543
 TI De novo lipogenesis in adipose tissue of lean and obese women: application
 of deuterated water and isotope ratio mass spectrometry.
 AU Guo Z K; Cella L K; Baum C; Ravussin E; Schoeller D A
 CS Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
 SO International journal of obesity and related metabolic disorders : journal
 of the International Association for the Study of Obesity, (2000
 Jul) 24 (7) 932-7.
 Journal code: 9313169. ISSN: 0307-0565.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Space Life Sciences
 EM 200010
 ED Entered STN: 20001019
 Last Updated on STN: 20011023
 Entered Medline: 20001012
 AB OBJECTIVE: To evaluate the feasibility of using deuterated water and
 isotope ratio mass spectrometry to measure de novo fatty acid synthesis in
 adipose tissue, and to compare this parameter in obese and lean women.
 SUBJECTS: Six lean and six obese premenopausal Caucasian women in the main
 study and three obese Pima Indians in a pilot study. MEASUREMENTS:
 Deuterated water was administered orally twice daily for 14 days to create
 stable deuterium enrichment in body water, during which series of blood
 samples were collected to measure body water deuterium enrichment and
 deuterium incorporation into plasma total Triacylglycerol (TG) fatty acids
 and total cholesterol. Subcutaneous fat at different sites were sampled
 at the beginning and the end of deuterium administration to measure
 deuterium incorporation into TG fatty acids. RESULTS: Fractional de novo
 synthesis rate of TG fatty acids in adipose tissue was 0.014+/-0.005 and
 0.014+/-0.007% in lean and obese Caucasian women, corresponding to 2+/-0.7
 and 5.6+/-3.2 g (P=0.3) of fatty acids synthesized daily, respectively.
 Plasma TG fatty acids and cholesterol synthesis rates were comparable to
 those reported previously. A pilot study showed that de novo lipid
 synthesis in adipose tissue of obese Pima Indians was also quantitatively
 minor. CONCLUSION: Human adipose tissue, like the liver, does not make a
 major contribution to whole body lipogenesis under eucaloric conditions.

A combination of deuterated water and isotope ratio mass spectrometry is a useful research tool for studying accumulation of de novo synthesized lipids in human adipose tissue.

ST Non-programmatic
 CT Check Tags: Comparative Study; Female; Male
 Adipocytes: PH, physiology
 *Adipose Tissue: PH, physiology
 Adult
 Arizona
 Body Composition: PH, physiology
 Cholesterol: BL, blood
 Cholesterol: CH, chemistry
 *Deuterium Oxide: AD, administration & dosage
 Deuterium Oxide: DU, diagnostic use
 *Fatty Acids: BI, biosynthesis
 Fatty Acids: BL, blood
 Fatty Acids: CH, chemistry
 Feasibility Studies
 Humans
 Indians, North American
 Obesity: EH, ethnology
 *Obesity: ME, metabolism
 Pilot Projects
 *Spectrum Analysis, Mass: MT, methods
 RN 57-88-5 (Cholesterol); 7789-20-0 (Deuterium Oxide)
 CN 0 (Fatty Acids)

L55 ANSWER 2 OF 37 MEDLINE on STN
 AN 2000029095 MEDLINE
 DN PubMed ID: 10563355
 TI Enzymatic synthesis of [14C]ceramide, [14C]glycosphingolipids, and omega-aminoceramide.
 AU Ito M; Mitsutake S; Tani M; Kita K
 CS Laboratory of Marine Biochemistry, Faculty of Agriculture, Kyushu University, Fukuoka, Japan.
 SO Methods in enzymology, (2000) 311 682-9.
 Journal code: 0212271. ISSN: 0076-6879.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199912
 ED Entered STN: 20000113
 Last Updated on STN: 20000113
 Entered Medline: 19991215
 CT Amidohydrolases: ME, metabolism
 Carbon Radioisotopes
 *Ceramides: BI, biosynthesis
 *Glycosphingolipids: BI, biosynthesis
 *Isotope Labeling
 Research Support, Non-U.S. Gov't
 CN 0 (Carbon Radioisotopes); 0 (Ceramide)s; 0 (Glycosphingolipids); EC 3.5. (Amidohydrolases)

L55 ANSWER 3 OF 37 MEDLINE on STN
 AN 2000029087 MEDLINE
 DN PubMed ID: 10563347
 TI Synthesis of key precursors of radiolabeled sphingolipids.
 AU Bielawska A; Szulc Z; Hannun Y A
 CS Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA.
 SO Methods in enzymology, (2000) 311 518-35.
 Journal code: 0212271. ISSN: 0076-6879.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English

FS Priority Journals
 EM 199912
 ED Entered STN: 20000113
 Last Updated on STN: 20000113
 Entered Medline: 19991215
 CT Carbon Radioisotopes
 *Ceramides: CH, chemistry
 *Isotope Labeling
 *Sphingolipids: BI, biosynthesis
 *Sphingomyelins: CH, chemistry
 *Sphingosine: CH, chemistry
 Stereoisomerism
 Tritium
 RN 10028-17-8 (Tritium); 123-78-4 (Sphingosine)
 CN 0 (Carbon Radioisotopes); 0 (Ceramide)s; 0 (Sphingolipids); 0 (Sphingomyelins)

L55 ANSWER 4 OF 37 MEDLINE on STN
 AN 1998382434 MEDLINE
 DN PubMed ID: 9714781
 TI Use of deuterium oxide to measure de novo fatty acid synthesis in normal subjects consuming different dietary fatty acid composition1.
 AU Konrad S D; Cook S L; Goh Y K; French M A; Clandinin M T
 CS Nutrition and Metabolism Research Group, University of Alberta, Edmonton, Alberta T6G 2P5, Canada.
 SO Biochimica et biophysica acta, (1998 Jul 31) 1393 (1) 143-52.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199810
 ED Entered STN: 19981020
 Last Updated on STN: 19981020
 Entered Medline: 19981002
 AB The effect of dietary linoleic (C18:2n-6) and palmitic acids (C16:0) on rate of hepatic de novo fatty acid synthesis was assessed in normal subjects. The diet was formulated to provide combinations of high and low levels of C18:2n-6 and C16:0. After 21 days of diet treatment, plasma triacylglycerol level and incorporation of deuterium into the plasma very low density lipoprotein triacylglycerol (VLDL-TG) pool over 24 hours was measured. Plasma triacylglycerol levels were within the normal range. Increasing dietary intake of linoleic acid decreased plasma triacylglycerol level when subjects consumed a low level of dietary palmitic acid. The relative and net amount of de novo synthesized fatty acid in the plasma VLDL-TG pool was not influenced by the diet treatments. A relationship between plasma triacylglycerol level and rate of hepatic de novo fatty acid synthesis was observed.
 CT Check Tags: Female; Male
 Adult
 *Deuterium Oxide
 *Dietary Fats: AD, administration & dosage
 Dietary Fats: AN, analysis
 *Fatty Acids: BI, biosynthesis
 Humans
 Linoleic Acid: AD, administration & dosage
 Linoleic Acid: AN, analysis
 *Liver: ME, metabolism
 Palmitic Acid: AD, administration & dosage
 Palmitic Acid: AN, analysis
 Research Support, Non-U.S. Gov't
 *Triglycerides: AN, analysis
 Triglycerides: BL, blood
 RN 2197-37-7 (Linoleic Acid); 57-10-3 (Palmitic Acid); 7789-20-0 (Deuterium Oxide)
 CN 0 (Dietary Fats); 0 (Fatty Acids); 0 (Triglycerides)

L55 ANSWER 5 OF 37 MEDLINE on STN
 AN 1998272311 MEDLINE
 DN PubMed ID: 9610780
 TI Validation of deuterium incorporation against sterol balance for measurement of human cholesterol biosynthesis.
 AU Jones P J; Ausman L M; Croll D H; Feng J Y; Schaefer E A; Lichtenstein A H
 CS School of Dietetics and Human Nutrition, Faculty of Agricultural and Environmental Sciences, McGill University, Ste-Anne-de-Bellevue, Quebec, Canada.
 SO Journal of lipid research, (1998 May) 39 (5) 1111-7.
 Journal code: 0376606. ISSN: 0022-2275.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199808
 ED Entered STN: 19980910
 Last Updated on STN: 19980910
 Entered Medline: 19980828
 AB To examine the validity of the deuterium (D) incorporation technique for measurement of human cholesterol synthesis rates, D uptake from D2O into cholesterol was compared to sterol balance in 13 subjects each under three controlled diet settings. Subjects (age 62 +/- 3.6 yr, body weight 74 +/- 4.0 kg, BMI 27 +/- 1.4) consumed weight maintenance diets enriched in either corn oil, beef tallow, or stick corn oil margarine over a 5-week period. During the final week of the study period, subjects were given 1.2 g/D2O per kg body water. D enrichment was measured in plasma water and total cholesterol over 24 h. Also, during the final week, dietary intake and fecal elimination rates of cholesterol were assessed over one 6-day period to calculate sterol balance. There was no significant difference ($t = 0.858$, $P = 0.397$) between D incorporation into cholesterol (1,183 +/- 92 mg/day) and sterol balance (1,316 +/- 125 mg/day). Among diets, net cholesterol biosynthesis measured by D incorporation agreed ($r = 0.745$, $P = 0.0001$) with values derived from sterol balance. The degree of association between methods was not influenced by the wide range of fatty acid composition of the diet fat. These data demonstrate the utility of the simple, non-restrictive deuterium incorporation method as a reliable means of determining cholesterol biosynthesis in free-living humans.
 CT Check Tags: Female; Male
 Adult
 Aged
 *Cholesterol: BI, biosynthesis
 *Deuterium Oxide: PD, pharmacology
 Dietary Fats: ME, metabolism
 Humans
 *Indicators and Reagents: PK, pharmacokinetics
 Middle Aged
 Reproducibility of Results
 Research Support, Non-U.S. Gov't
 Research Support, U.S. Gov't, Non-P.H.S.
 RN 57-88-5 (Cholesterol); 7789-20-0 (Deuterium Oxide)
 CN 0 (Dietary Fats); 0 (Indicators and Reagents)

L55 ANSWER 6 OF 37 MEDLINE on STN
 AN 97161767 MEDLINE
 DN PubMed ID: 9008871
 TI Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatographic/mass spectrometric techniques.
 AU Diraison F; Pachiaudi C; Beylot M
 CS Laboratoire de Physiologie Metabolique et Renale, Faculte de Medecine R. Laennec, Lyon, France.
 SO Journal of mass spectrometry : JMS, (1997 Jan) 32 (1) 81-6.
 Journal code: 9504818. ISSN: 1076-5174.
 CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199702
 ED Entered STN: 19970305
 Last Updated on STN: 19970305
 Entered Medline: 19970219
 AB Lipogenesis and cholesterol synthesis can be studied by measuring the incorporation into fatty acids and cholesterol of deuterium from deuterated water. This has been previously achieved in human subjects using low levels of deuterium enrichment in plasma water, and thus in fatty acids and cholesterol. For the measurement of enrichment in lipids, this required the use of isotope ratio mass spectrometry, a tedious and time-consuming technique. It is shown that these measurements can be performed using the much simpler gas chromatography/mass spectrometry if higher, but always safe, deuterium enrichments in plasma water are obtained. Normal subjects ingested deuterated water in order to obtain stable enrichment in plasma water of 0.3% during a 60 h period. Enrichment in palmitate of plasma triglycerides (TG) plateaued (0.6-0.76%) whereas plasma cholesterol enrichment increased progressively [0.32 +/- 0.08% (12 h) to 0.78 +/- 0.18% (60 h)]. Endogenous synthesis was estimated to contribute, in post-absorptive subjects, 8-10% of the plasma TG pool and 3-5% of plasma free cholesterol pool. These data agree with results obtained previously using isotope ratio mass spectrometry. The present method will be useful for studies of normal and abnormal lipid metabolism in humans.
 CT Cholesterol: AN, analysis
 *Cholesterol: BI, biosynthesis
 Cholesterol: BL, blood
 Deuterium Oxide: BL, blood
 *Deuterium Oxide: ME, metabolism
 Glucose: AN, analysis
 Humans
 Lactic Acid: AN, analysis
 Lactic Acid: BL, blood
 Lipids: AN, analysis
 *Lipids: BI, biosynthesis
 Lipids: BL, blood
 *Mass Fragmentography
 Palmitic Acid: AN, analysis
 Palmitic Acid: BL, blood
 Research Support, Non-U.S. Gov't
 Triglycerides: AN, analysis
 Triglycerides: BL, blood
 RN 50-21-5 (Lactic Acid); 50-99-7 (Glucose); 57-10-3 (Palmitic Acid); 57-88-5 (Cholesterol); 7789-20-0 (Deuterium Oxide)
 CN 0 (Lipids); 0 (Triglycerides)
 L55 ANSWER 7 OF 37 MEDLINE on STN
 AN 97091885 MEDLINE
 DN PubMed ID: 8937551
 TI Stable isotopes and mass isotopomer study of fatty acid and cholesterol synthesis. A review of the MIDA approach.
 AU Lee W N
 CS Research and Education Institute, Harbor-UCLA Medical Center, Torrance 90502, USA.
 NC R01-DK46353 (NIDDK)
 SO Advances in experimental medicine and biology, (1996) 399 95-114. Ref: 31
 Journal code: 0121103. ISSN: 0065-2598.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals

EM 199703
 ED Entered STN: 19970313
 Last Updated on STN: 19970313
 Entered Medline: 19970303
 CT Biopolymers
 Carbon Isotopes
 *Cholesterol: BI, biosynthesis
 Deuterium
 *Fatty Acids: BI, biosynthesis
 *Isotopes
 Mathematics
 Research Support, U.S. Gov't, P.H.S.
 RN 57-88-5 (Cholesterol); 7782-39-0 (Deuterium)
 CN 0 (Biopolymers); 0 (Carbon Isotopes); 0 (Fatty Acids); 0 (Isotopes)

L55 ANSWER 8 OF 37 MEDLINE on STN
 AN 96292203 MEDLINE
 DN PubMed ID: 8692014
 TI In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated.
 AU Diraison F; Pachiaudi C; Beylot M
 CS INSERM U. 197, Faculte de Medecine Alexis Carrel, Lyon, France.
 SO Metabolism: clinical and experimental, (1996 Jul) 45 (7) 817-21.
 Journal code: 0375267. ISSN: 0026-0495.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199608
 ED Entered STN: 19960911
 Last Updated on STN: 19960911
 Entered Medline: 19960828
 AB Fractional lipid synthesis can be measured using the incorporation of deuterium from deuterated water. The calculations require knowledge of the maximum incorporation number (N) of deuterium atoms in the molecules synthesized. For both tissue palmitate and cholesterol, N values have been found to be higher during in vivo versus in vitro experiments. We determined the N values to be used for measuring the fractional synthesis of plasma cholesterol and of palmitate triglycerides (TG). Rats were given drinking water enriched (7% to 10%) with deuterated water, and N was determined from the mass isotopomer distributions of plasma cholesterol and plasma TG palmitate and the deuterium enrichment of plasma water. We found N to be 21 for palmitate and 27 for cholesterol. These values agree with those reported for tissue palmitate and cholesterol in vivo, and are higher than values found in vitro. We also found large deuterium enrichments in plasma glucose and in liver lactate and pyruvate. We suggest that, compared with in vitro studies, in vivo metabolism of these compounds leads to an additional pathway of incorporation of deuterium into lipids through deuterium-labeled acetyl coenzyme A (CoA). This could explain why N values are higher in vivo than in vitro.
 CT Check Tags: Male
 Acetyl Coenzyme A: ME, metabolism
 Animals
 Blood Chemical Analysis: MT, methods
 Blood Glucose: ME, metabolism
 Cholesterol: BI, biosynthesis
 *Cholesterol: BL, blood
 Deuterium: ME, metabolism
 *Deuterium Oxide: ME, metabolism
 *Fatty Acids: BI, biosynthesis
 Fatty Acids: BL, blood
 Lactates: ME, metabolism
 Lactic Acid
 Liver: ME, metabolism
 Mass Fragmentography

Palmitates: BL, blood
 Pyruvates: ME, metabolism
 Pyruvic Acid
 Rats
 Rats, Sprague-Dawley
 Research Support, Non-U.S. Gov't.
 Triglycerides: BL, blood
 RN 127-17-3 (Pyruvic Acid); 50-21-5 (Lactic Acid); 57-88-5 (Cholesterol);
 72-89-9 (Acetyl Coenzyme A); 7782-39-0 (Deuterium); 7789-20-0 (Deuterium
 Oxide)
 CN 0 (Blood Glucose); 0 (Fatty Acids); 0 (Lactates); 0 (Palmitates); 0
 (Pyruvates); 0 (Triglycerides)

L55 ANSWER 9 OF 37 MEDLINE on STN
 AN 94358640 MEDLINE
 DN PubMed ID: 8077848
 TI Interaction of dietary fat saturation and cholesterol level on cholesterol
 synthesis measured using deuterium incorporation.
 AU Jones P J; Lichtenstein A H; Schaefer E J
 CS Division of Human Nutrition, University of British Columbia, Vancouver,
 Canada.
 NC HL39326 (NHLBI)
 SO Journal of lipid research, (1994 Jun) 35 (6) 1093-101.
 Journal code: 0376606. ISSN: 0022-2275.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199410
 ED Entered STN: 19941013
 Last Updated on STN: 19941013
 Entered Medline: 19941003
 AB To examine interactive effects of dietary fat saturation and cholesterol
 level on serum lipids and de novo cholesterol synthesis, moderately
 hypercholesterolemic subjects were fed solid-foods diets containing 30%
 fat (80 mg C.1000 Kcal-1) in which 2/3 fat was either corn oil or beef
 tallow, with and without 120 mg C.1000 Kcal-1, for 5 wk. At the end of
 each diet period, subjects were given deuterium (D) oxide orally and de
 novo cholesterol synthesis was measured over 24 h from D incorporation
 into cholesterol as fractional synthesis rates (FSR) and absolute
 synthetic rate (ASR) into the rapid exchangeable cholesterol pool. Plasma
 total and low density lipoprotein levels were elevated ($P < 0.01$) with
 both beef tallow and cholesterol feeding. High density lipoprotein (HDL)
 levels were not influenced by fat saturation or cholesterol level;
 however, HDL was higher with addition of cholesterol to corn oil versus
 beef tallow ($P < 0.02$). Plasma triglycerides were higher ($P < 0.02$) with
 beef tallow feeding but were not influenced by cholesterol level. FSR was
 increased ($P < 0.02$) by feeding corn oil, versus beef fat, but not by
 dietary cholesterol level. Calculated cholesterol pools sizes did not
 differ across groups; however, ASR was also elevated with corn oil versus
 beef tallow feeding ($P < 0.02$). Results indicate that corn oil feeding
 lowers circulating cholesterol by mechanisms other than reduced synthesis,
 and that cholesterol at the level of supplementation used is not
 associated with feedback inhibition of cholesterol synthesis. However, with
 the exception of HDL levels, dietary fat saturation and cholesterol levels
 do not interactively influence circulating lipoprotein cholesterol levels
 and cholesterol synthesis.
 CT Aged
 Animals
 Cattle
 *Cholesterol: BI, biosynthesis
 Cholesterol: BL, blood
 *Cholesterol, Dietary: AD, administration & dosage
 Corn Oil: AD, administration & dosage
 *Deuterium: DU, diagnostic use
 *Dietary Fats: AD, administration & dosage

Fats: AD, administration & dosage
 Fatty Acids: AD, administration & dosage
 Fatty Acids, Monounsaturated: AD, administration & dosage
 Fatty Acids, Unsaturated: AD, administration & dosage
 Humans
 Lipoproteins, HDL Cholesterol: BL, blood
 Lipoproteins, LDL Cholesterol: BL, blood
 Meat
 Middle Aged
 Research Support, Non-U.S. Gov't
 Research Support, U.S. Gov't, Non-P.H.S.
 Research Support, U.S. Gov't, P.H.S.
 Triglycerides: BL, blood
 RN 57-88-5 (Cholesterol); 61789-97-7 (tallow); 7782-39-0 (Deuterium);
 8001-30-7 (Corn Oil)
 CN 0 (Cholesterol, Dietary); 0 (Dietary Fats); 0 (Fats); 0 (Fatty Acids); 0
 (Fatty Acids, Monounsaturated); 0 (Fatty Acids, Unsaturated); 0
 (Lipoproteins, HDL Cholesterol); 0 (Lipoproteins, LDL Cholesterol); 0
 (Triglycerides)
 L55 ANSWER 10 OF 37 MEDLINE on STN
 AN 93152551 MEDLINE
 DN PubMed ID: 8381301
 TI Human cholesterol synthesis measurement using deuterated water.
 Theoretical and procedural considerations.
 AU Jones P J; Leitch C A; Li Z C; Connor W E
 CS Division of Human Nutrition, University of British Columbia, Vancouver,
 Canada.
 SO Arteriosclerosis and thrombosis : a journal of vascular biology / American
 Heart Association, (1993 Feb) 13 (2) 247-53. Ref: 34
 Journal code: 9101388. ISSN: 1049-8834.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199303
 ED Entered STN: 19930326
 Last Updated on STN: 19930326
 Entered Medline: 19930308
 AB Human cholesterol synthesis is measurable as the rate of incorporation of
 deuterium derived from deuterium oxide (D2O) within the body water pool
 into plasma or erythrocyte cholesterol pools. Oral D2O equilibrates
 across body water, thus enabling extracellular sampling of pools (such as
 urine) to serve as accurate indicators of intracellular deuterium
 enrichments at the point of synthesis. Required doses of D2O fall below
 the threshold associated with negative side effects. Deuterium/carbon
 incorporation ratios into cholesterol during biosynthesis have been
 established that are applicable in humans. Models using unconstrained and
 constrained curve fitting permit improved flexibility in interpretation of
 deuterium-uptake kinetics. However, sample-size restrictions presently
 limit the ability of the technique to examine the kinetics within
 individual lipoprotein species. Correction of enrichment data for proton
 exchange during combustion and reduction phases of sample preparation is
 an additional important procedural concern. In summary, the
 deuterated-water procedure is a useful tool in studies of human
 cholesterol synthesis that offers the advantages of short measurement
 interval, relative noninvasiveness, and provision of a direct index of
 synthesis in comparison with other available techniques.
 CT Check Tags: Male
 Animals
 *Cholesterol: BI, biosynthesis
 *Deuterium: ME, metabolism
 Deuterium Oxide
 Humans

Methods
 Research Support, Non-U.S. Gov't
 Swine
 *Water: ME, metabolism
 RN 57-88-5 (Cholesterol); 7732-18-5 (Water); 7782-39-0 (Deuterium); 7789-20-0 (Deuterium Oxide)

L55 ANSWER 11 OF 37 MEDLINE on STN
 AN 93035907 MEDLINE
 DN PubMed ID: 1415685
 TI Isotopomer spectral analysis of triglyceride fatty acid synthesis in 3T3-L1 cells.
 AU Kharroubi A T; Masterson T M; Aldaghlis T A; Kennedy K A; Kelleher J K
 CS Department of Physiology, George Washington University Medical Center, Washington, District of Columbia 20037.
 NC AG-00412 (NIA)
 GM-33506 (NIGMS)
 SO American journal of physiology, (1992 Oct) 263 (4 Pt 1) E667-75..
 Journal code: 0370511. ISSN: 0002-9513.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199211
 ED Entered STN: 19930122
 Last Updated on STN: 19980206
 Entered Medline: 19921125

AB A new analysis of stable isotope data for biosynthesis reaction, isotopomer spectral analysis (ISA), is demonstrated. ISA is theoretically applicable for polymerization biosynthesis where data are collected using selected ion-monitoring gas chromatography-mass spectrometry. ISA utilizes the discrete spectrum of isotopomer abundances and the multinomial distribution to estimate two key parameters related to the biosynthesis. These parameters are 1) the dilution of the precursor immediately before biosynthesis and 2) the dilution of the newly synthesized product in the sampled compartment. Differentiated 3T3-L1 cells incorporated 2 mM [1,2-13C]acetate into triglyceride palmitate, yielding a spectrum of mass isotopomers of palmitate. The set of equations for the first nine isotopomers were solved for the two parameters using nonlinear regression. We found that precursor dilutions for acetate and glucose were constant over time, whereas the product dilution parameter increased with time, as expected for cells accumulating triglyceride palmitate. Mathematical procedures are presented for calculating 1) the predicted isotopomer fractional abundance values and 2) the correction for atoms other than the tracer atom in the mass ion.

CT 3T3 Cells
 Animals
 *Carbon Isotopes
 *Fatty Acids: BI, biosynthesis
 Mice
 Models, Biological
 Myristic Acid
 Myristic Acids: ME, metabolism
 Palmitates: ME, metabolism
 Regression Analysis
 Research Support, U.S. Gov't, P.H.S.
 *Spectrum Analysis: MT, methods
 *Triglycerides: BI, biosynthesis
 RN 544-63-8 (Myristic Acid)
 CN 0 (Carbon Isotopes); 0 (Fatty Acids); 0 (Myristic Acids); 0 (Palmitates); 0 (Triglycerides)

L55 ANSWER 12 OF 37 MEDLINE on STN
 AN 92044100 MEDLINE
 DN PubMed ID: 1940619
 TI Measurement of in vivo cholesterol synthesis from 2H2O: a rapid procedure

for the isolation, combustion, and isotopic assay of erythrocyte cholesterol.

AU Wong W W; Hachey D L; Feste A; Leggitt J; Clarke L L; Pond W G; Klein P D
CS Department of Pediatrics, Baylor College of Medicine, Houston, TX.
SO Journal of lipid research, (1991 Jun) 32 (6) 1049-56.
Journal code: 0376606. ISSN: 0022-2275.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199112
ED Entered STN: 19920124
Last Updated on STN: 19920124
Entered Medline: 19911204

AB A rapid preparative scale purification of erythrocyte free cholesterol has been developed for measurements of in vivo cholesterol synthesis from 2H2O. The quantity and purity of cholesterol obtained is suitable for combustion, zinc reduction of the water formed, and determination of deuterium isotopic content by gas isotope ratio mass spectrometry. The ability to detect and to quantitate a range of cholesterol synthesis rates is illustrated by measurements on young pigs receiving diets without and with added dietary cholesterol.

CT Animals
*Cholesterol: BI, biosynthesis
Cholesterol: BL, blood
Cholesterol: IP, isolation & purification
Cholesterol, Dietary: AD, administration & dosage
Chromatography, High Pressure Liquid: MT, methods
*Deuterium
*Erythrocytes: CH, chemistry
Humans
Research Support, U.S. Gov't, Non-P.H.S.
Spectrum Analysis, Mass: MT, methods
Swine
*Water: CH, chemistry

RN 57-88-5 (Cholesterol); 7732-18-5 (Water); 7782-39-0 (Deuterium)
CN 0 (Cholesterol, Dietary)

L55 ANSWER 13 OF 37 MEDLINE on STN
AN 90345294 MEDLINE
DN PubMed ID: 2200588
TI Use of deuterated water for measurement of short-term cholesterol synthesis in humans.

AU Jones P J
CS Division of Human Nutrition, School of Family and Nutritional Sciences, University of British Columbia, Vancouver, Canada.
SO Canadian journal of physiology and pharmacology, (1990 Jul) 68 (7) 955-9. Ref: 24
Journal code: 0372712. ISSN: 0008-4212.
CY Canada
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199009
ED Entered STN: 19901026
Last Updated on STN: 19901026
Entered Medline: 19900920

AB Previous methods for measurement of cholesterol synthesis de novo in humans have either required extended measurement periods or been indirect. Recently, a technique based on the rate of incorporation of deuterium from D2O into the plasma cholesterol pool has been developed. Following oral ingestion of D2O, deuterium enrichment over time in free plasma cholesterol after combustion and reduction was determined using isotope ratio mass spectrometry. This methodology enabled direct measurement of

plasma cholesterol synthesis over intervals as short as 4 h. The technique has been used to demonstrate changes in synthetic rate in response to feeding conditions and genetic influences. Fasting over 36 h resulted in markedly reduced deuterium uptake into cholesterol in healthy males. Diurnal variations in synthetic rate have also been identified, with elevated synthesis observed during nocturnal periods in both fed and fasted subjects. In addition, the influence of apolipoprotein E phenotype on cholesterol synthesis has been shown using this technique. Individuals carrying the apoprotein epsilon 2 allele demonstrated lower synthesis compared with those possessing the epsilon 4 allele. Thus, the deuterium incorporation technique for measuring cholesterol synthesis demonstrates potential as a valuable stable isotope method for human nutrition studies.

CT *Cholesterol: BI, biosynthesis

*Deuterium: DU, diagnostic use

Humans

Research Support, Non-U.S. Gov't

RN 57-88-5 (Cholesterol); 7782-39-0 (Deuterium)

L55 ANSWER 14 OF 37 MEDLINE on STN

AN 86104369 MEDLINE

DN PubMed ID: 3942765

TI Evidence for different isotopic enrichments of acetyl-CoA used for cholesterol synthesis in the liver and intestine: a study in the rat by mass fragmentography after intravenous infusion of [13C]acetate.

AU Ferezou J; Sulpice J C; Lutton C

SO Biochimica et biophysica acta, (1986 Feb 12) 875 (2) 227-35.

Journal code: 0217513. ISSN: 0006-3002.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198603

ED Entered STN: 19900321

Last Updated on STN: 19970203

Entered Medline: 19860319

AB Wistar rats were killed 4 h after an intravenous infusion of [1,2-13C]- and [1-14C]acetic acid sodium salt (39 mg, 12.5 microCi/ml, constant rate: 1.2 ml/h). At this time, labeled free cholesterol movements between the organs are still weak and cholesterol labeling in each tissue mainly originates from the in situ incorporation of the exogenous substrate. In male rats, the specific radioactivity of free cholesterol was found to be higher in the intestine (mucosa and wall) than in the liver and plasma. In female and in cholestyramine-fed male rats, cholesterol 14C labeling was close to that of male rats in the intestine, and was markedly higher in the liver. The same variations of 13C excess, calculated by mass fragmentography, indicated that there was no isotopic effect between 13C and 14C precursors. The advantage of this method consisted in obtaining the proportions of labeled molecules according to their molecular weight ($M + 1 - M + 11$) for each sample. Then the distribution of 13C atoms in newly synthesized cholesterol was assessed in each sterogenesis site. In the intestine, about 3/4 of the 13C atoms were found in molecules of weight of at least $M + 4$ (after incorporation of at least two labeled acetate units). This proportion was only 1/3 in hepatic and plasma free cholesterol. These distinct 13C-labeling patterns clearly indicate that local variations occurred in the isotopic enrichment of acetyl-CoA used for cholesterol formation. Whatever the experimental conditions of this study, cholesterol was synthesized from an acetyl-CoA more 13C enriched in the intestine than in the liver. Such variations probably result from the different dilutions of exogenous acetyl-CoA by the endogenous pool in the liver and intestine. Consequently, the 14C or 13C incorporations measured in the liver and intestinal sterols do not account for absolute rates of cholesterol production by these organs. This study also indicated that after a few hours of infusion, free cholesterol labeling in the plasma originated mainly from cholesterol newly formed in the liver, even when acetate incorporation into cholesterol was higher in the intestine than in the liver.

CT Check Tags: Female; Male
 Acetic Acid
 Acetic Acids: ME, metabolism
 *Acetyl Coenzyme A: ME, metabolism
 Animals
 *Cholesterol: BI, biosynthesis
 *Intestines: ME, metabolism
 *Isotope Labeling
 *Liver: ME, metabolism
 Mass Fragmentography
 Mathematics
 Rats
 Rats, Inbred Strains

RN 57-88-5 (Cholesterol); 64-19-7 (Acetic Acid); 72-89-9 (Acetyl Coenzyme A)
 CN 0 (Acetic Acids)

L55 ANSWER 15 OF 37 MEDLINE on STN
 AN 85258111 MEDLINE
 DN PubMed ID: 3894050
 TI Effect of drugs, peptide hormones and lipogenic precursors on the relative incorporation of [3H]H2O and carbon into hepatic cholesterol.
 AU Bjornsson O G; Pullinger C R; Gibbons G F
 SO FEBS letters, (1985 Aug 5) 187 (2) 302-6.
 Journal code: 0155157. ISSN: 0014-5793.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198509
 ED Entered STN: 19900320
 Last Updated on STN: 19970203
 Entered Medline: 19850924

AB Measurement of the weight of desmosterol produced during its biosynthesis in the presence of tritiated water and triparanol has permitted a direct determination of the relative flux of carbon and tritium (the H/C ratio) into sterol in hepatocytes. The H/C ratio increased with time of incubation irrespective of the nutritional state of the donor animals. This increase was more marked in hepatocytes from starved animals. Pyruvate and lactate increased, and glucagon decreased, the sterol H/C ratio. Addition of pyruvate to incubations containing glucagon resulted in a 32-67% increase in the H/C ratio depending upon nutritional status. Insulin had no effect whilst (-)-hydroxycitrate decreased the ratio by 25%.

CT Check Tags: In Vitro
 Animals
 *Carbon: ME, metabolism
 *Cholesterol: BI, biosynthesis
 Citrates: PD, pharmacology
 Fasting
 Glucagon: PD, pharmacology
 Insulin: PD, pharmacology
 Lactates: PD, pharmacology
 Lactic Acid
 Liver: DE, drug effects
 *Liver: ME, metabolism
 Pyruvates: PD, pharmacology
 Pyruvic Acid
 Rats
 Research Support, Non-U.S. Gov't
 *Tritium: ME, metabolism

RN 10028-17-8 (Tritium); 11061-68-0 (Insulin); 127-17-3 (Pyruvic Acid); 50-21-5 (Lactic Acid); 57-88-5 (Cholesterol); 6205-14-7 (hydroxycitric acid); 7440-44-0 (Carbon); 9007-92-5 (Glucagon)
 CN 0 (Citrates); 0 (Lactates); 0 (Pyruvates)

L55 ANSWER 16 OF 37 MEDLINE on STN

AN 83100402 MEDLINE
 DN PubMed ID: 6758778
 TI Differential hydrogen exchange during the fatty acid synthetase reaction: deuterium distribution of fatty acids synthesized from [2-2H₂]malonyl-CoA.
 AU Saito K; Kawaguchi A; Nozoe S; Seyama Y; Okuda S
 SO Biochemical and biophysical research communications, (1982 Oct 15) 108 (3) 995-1001.
 Journal code: 0372516. ISSN: 0006-291X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198302
 ED Entered STN: 19900317
 Last Updated on STN: 19900317
 Entered Medline: 19830214
 CT Brevibacterium
 *Deuterium: ME, metabolism
 *Fatty Acid Synthetase Complex: ME, metabolism
 *Fatty Acids: BI, biosynthesis
 *Hydrogen: ME, metabolism
 Malonyl Coenzyme A: ME, metabolism
 Mass Fragmentography
 Research Support, Non-U.S. Gov't
 Saccharomyces cerevisiae
 RN 1333-74-0 (Hydrogen); 524-14-1 (Malonyl Coenzyme A); 7782-39-0 (Deuterium)
 CN 0 (Fatty Acids); EC 6.- (Fatty Acid Synthetase Complex)

L55 ANSWER 17 OF 37 MEDLINE on STN

AN 81175008 MEDLINE
 DN PubMed ID: 7220494
 TI A simple method for the preparation of phosphatidylcholine labelled at 2-acyl position.
 AU Connor A M; Brimble P D; Choy P C
 SO Preparative biochemistry, (1981) 11 (1) 91-7.
 Journal code: 1276634. ISSN: 0032-7484.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198106
 ED Entered STN: 19900316
 Last Updated on STN: 19900316
 Entered Medline: 19810613
 AB Phosphatidylcholine with a labelled acyl group at 2 position was prepared enzymatically from lysophosphatidylcholine and labelled fatty acids. Under optimal conditions, over 90% of [5,6,8,9,11,12,14,15-3H] arachidonic acid, [9,10-3H] palmitic acids, [1-14C] linoleic acid or [9,10-3H] oleic acid was incorporated into the phosphatidylcholine, and the incorporation was quantitative up to 500 nmol of [1-14C] linoleic acid. Analysis of the labelled phosphatidylcholine formed indicated that radioactivity was incorporated exclusively at 2-acyl position.
 CT Animals
 Arachidonic Acids: ME, metabolism
 Carbon Radioisotopes
 *Isotope Labeling: MT, methods
 Linoleic Acids: ME, metabolism
 Microsomes, Liver: ME, metabolism
 Oleic Acids: ME, metabolism
 Palmitic Acids: ME, metabolism
 *Phosphatidylcholines
 *Phosphatidylcholines: BI, biosynthesis
 Rats
 Research Support, Non-U.S. Gov't
 Tritium
 RN 10028-17-8 (Tritium)

CN 0 (Arachidonic Acids); 0 (Carbon Radioisotopes); 0 (Linoleic Acids); 0 (Oleic Acids); 0 (Palmitic Acids); 0 (Phosphatidylcholines)

L55 ANSWER 18 OF 37 MEDLINE on STN
 AN 77215888 MEDLINE
 DN PubMed ID: 327543
 TI Mechanism of carbon isotope fractionation associated with lipid synthesis.
 AU DeNiro M J; Epstein S
 SO Science, (1977 Jul 15) 197 (4300) 261-3.
 Journal code: 0404511. ISSN: 0036-8075.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197708
 ED Entered STN: 19900314
 Last Updated on STN: 20010625
 Entered Medline: 19770825

AB The low carbon-13/carbon-12 ratio of lipids is shown to result from isotopic fractionation during the oxidation of pyruvate to acetyl coenzyme A. In vitro analysis of the kinetic isotope effects of this reaction indicates that there will be a large, temperature-dependent difference in the carbon-13/carbon-12 ratio between the methyl and carbonyl carbon atoms of acetyl coenzyme A and between those carbon atoms of lipid components which derive from them.

CT Acetates: ME, metabolism
 *Carbon Isotopes: ME, metabolism
 *Carboxy-Lyases: ME, metabolism
 Escherichia coli: ME, metabolism
 Glucose: ME, metabolism
 Kinetics
 *Lipids: BI, biosynthesis
 *Pyruvate Decarboxylase: ME, metabolism
 Pyruvates: ME, metabolism
 Research Support, U.S. Gov't, Non-P.H.S.
 Saccharomyces cerevisiae: EN, enzymology

RN 50-99-7 (Glucose)

CN 0 (Acetates); 0 (Carbon Isotopes); 0 (Lipids); 0 (Pyruvates); EC 4.1.1. (Carboxy-Lyases); EC 4.1.1.1 (Pyruvate Decarboxylase)

L55 ANSWER 19 OF 37 MEDLINE on STN
 AN 77176576 MEDLINE
 DN PubMed ID: 1025874
 TI [Intensity of incorporation of 2-C14-acetate into the cerebroside and gangliosides of the brain and spinal cord of rabbits in experimental allergic encephalomyelitis].
 Intensivnost' vklucheniia 2-C14-atsetata v tserebrozidy i gangliozydy golovnogo mozga i spinnogo mozga krolikov pri eksperimental'nom allergicheskom entsefalomielite.
 AU Taranova N P; Katsnel'son I P
 SO Voprosy meditsinskoi khimii, (1976 Jan-Feb) 22 (1) 108-12.
 Journal code: 0416601. ISSN: 0042-8809.
 CY USSR
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 197706
 ED Entered STN: 19900313
 Last Updated on STN: 20000303
 Entered Medline: 19770630

AB In rabbits the acute form of experimental allergic encephalomyelitis was caused by inoculation of emulsion of homologous myelin from spinal cord with Freund's adjuvant. In terminal paralytic period of the disease the animals were subcutaneously administered with 2-14C-acetate and a dose 50 micronCi per 100 g of body weight 2 hrs before death. From lumbar and stem sections of the central nervous system purified fractions of

cerebrosides and gangliosides were isolated and their specific radioactivity was determined. The intensity of the cerebrosides synthesis was found to be distinctly decreased not only in the more impaired lumbar region but also in the stem section of the central nervous system, where the centers of demyelination were not observed. The intensity of the gangliosides synthesis was also markedly decreased, in spite of that their content was not altered in the central nervous system under experimental allergic encephalomyelitis.

CT Check Tags: Male
 Acetates: ME, metabolism
 Acute Disease
 Animals
 Brain Chemistry
 *Brain Stem: ME, metabolism
 *Carbon Radioisotopes: DU, diagnostic use
 *Cerebrosides: BI, biosynthesis
 Cerebrosides: IP, isolation & purification
 Chromatography, Thin Layer
 *Encephalomyelitis, Autoimmune, Experimental: ME, metabolism
 English Abstract
 *Gangliosides: BI, biosynthesis
 Gangliosides: IP, isolation & purification
 Lumbosacral Region
 Rabbits
 Spinal Cord: AN, analysis
 *Spinal Cord: ME, metabolism
 CN 0 (Acetates); 0 (Carbon Radioisotopes); 0 (Cerebrosides); 0 (Gangliosides)

L55 ANSWER 20 OF 37 MEDLINE on STN

AN 77109534 MEDLINE

DN PubMed ID: 835772

TI Enhancement of biliary phospholipid radioactivity by intestinal administration of labeled precursors of hepatic lecithin synthesis.

AU King W 3rd; Tompkins R K

SO American journal of surgery, (1977 Jan) 133 (1) 127-33.

Journal code: 0370473. ISSN: 0002-9610.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 197703

ED Entered STN: 19900313

Last Updated on STN: 19900313

Entered Medline: 19770315

AB An animal model is used to study the effects of different radioactive precursors of lecithin, administered intestinally, upon biliary lecithin synthesis. Choline caused greater biliary lecithin radioactivity than choline-labeled lecithin or palmitic acid. The clinical application of this finding is discussed with relation to patients with gallstones or potentially lithogenic bile. Oral administration of choline may increase biliary lecithin concentration and, thus, cholesterol-holding capacity in this patient group, thereby changing the character of the bile to a non-lithogenic state.

CT Animals

*Bile Acids and Salts: ME, metabolism

*Carbon Radioisotopes: ME, metabolism

Cholelithiasis: ET, etiology

*Choline: PD, pharmacology

Injectons

Intestines

*Liver: ME, metabolism

Models, Biological

Palmitic Acids: AD, administration & dosage

*Palmitic Acids: PD, pharmacology

Phosphatidylcholines: BI, biosynthesis

*Phospholipids: BI, biosynthesis

Swine
 RN 62-49-7 (Choline)
 CN 0 (Bile Acids and Salts); 0 (Carbon Radioisotopes); 0 (Palmitic Acids); 0 (Phosphatidylcholines); 0 (Phospholipids)

L55 ANSWER 21 OF 37 MEDLINE on STN
 AN 74062356 MEDLINE
 DN PubMed ID: 4587725
 TI An efficient biosynthetic method to prepare fatty acyl chains highly enriched with ¹³C.
 AU Cronan J E Jr; Batchelor J G
 SO Chemistry and physics of lipids, (1973 Oct) 11 (3) 196-202.
 Journal code: 0067206. ISSN: 0009-3084.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197402
 ED Entered STN: 19900310
 Last Updated on STN: 19900310
 Entered Medline: 19740222

CT Acetates: ME, metabolism
 *Carbon Isotopes
 Carbon Radioisotopes
 Citrate (si)-Synthase
 Escherichia coli: ME, metabolism
 Evaluation Studies
 *Fatty Acids: BI, biosynthesis
 Isotope Labeling
 Magnetic Resonance Spectroscopy
 Methods
 Mutation
 Transduction, Genetic

CN 0 (Acetates); 0 (Carbon Isotopes); 0 (Carbon Radioisotopes); 0 (Fatty Acids); EC 4.1.3.7 (Citrate (si)-Synthase)

L55 ANSWER 22 OF 37 MEDLINE on STN
 AN 73216685 MEDLINE
 DN PubMed ID: 4717997
 TI Labeling plasma lipoproteins with radioactive cholesterol.
 AU Sodhi H S; Kudchodkar B J
 SO Journal of laboratory and clinical medicine, (1973 Jul) 82 (1) 111-24.
 Journal code: 0375375. ISSN: 0022-2143.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 197309
 ED Entered STN: 19900310
 Last Updated on STN: 19900310
 Entered Medline: 19730913

CT Check Tags: Female; Male
 Acetates: AD, administration & dosage
 Administration, Oral
 Adult
 Blood Protein Disorders: BL, blood
 Carbon Isotopes
 Cholesterol: AD, administration & dosage
 Cholesterol: AN, analysis
 Cholesterol: BI, biosynthesis
 *Cholesterol: BL, blood
 Cholesterol: ME, metabolism
 Ethanol: AD, administration & dosage
 Feces: AN, analysis
 Humans

Hyperlipidemia: BL, blood
 Injections, Intravenous
 *Isotope Labeling
 Lipoproteins: BI, biosynthesis
 *Lipoproteins: BL, blood
 Methods
 Mevalonic Acid: AD, administration & dosage
 Middle Aged
 Tritium
 Xanthomatosis: BL, blood
 RN 10028-17-8 (Tritium); 150-97-0 (Mevalonic Acid); 57-88-5 (Cholesterol);
 64-17-5 (Ethanol)
 CN 0 (Acetates); 0 (Carbon Isotopes); 0 (Lipoproteins)

L55 ANSWER 23 OF 37 MEDLINE on STN
 AN 73145444 MEDLINE
 DN PubMed ID: 4735044
 TI A simple biosynthetic method for the preparation of glycerol-labelled
 phosphatidylcholine.
 AU Parthasarathy S; Ganguly J
 SO Biochimica et biophysica acta, (1973 Jan 19) 296 (1) 62-4.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197305
 ED Entered STN: 19900310
 Last Updated on STN: 19900310
 Entered Medline: 19730518
 CT *Carbon Isotopes
 Chromatography, Thin Layer
 Darkness
 Glycerides: ME, metabolism
 *Glycerol
 Glycerol: ME, metabolism
 Isotope Labeling
 Methods
 *Phosphatidylcholines: BI, biosynthesis
 Phosphatidylcholines: IP, isolation & purification
 Phospholipids: ME, metabolism
 Plants: ME, metabolism
 Seeds: ME, metabolism
 Soybeans
 RN 56-81-5 (Glycerol)
 CN 0 (Carbon Isotopes); 0 (Glycerides); 0 (Phosphatidylcholines); 0
 (Phospholipids)

L55 ANSWER 24 OF 37 MEDLINE on STN
 AN 72098476 MEDLINE
 DN PubMed ID: 5167797
 TI [Use of different C 14 precursors for the biosynthesis of labelled
 fucidin].
 Ispol'zovanie rallichnykh C 14 -predshestvennikov dlia biosinteza
 mechenogo fuzidina.
 AU Grianova N S; Afonin V I; Sazykin Iu O
 SO Antibiotiki, (1971 Sep) 16 (9) 775-7.
 Journal code: 0375020. ISSN: 0003-5637.
 CY USSR
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 197204
 ED Entered STN: 19900310
 Last Updated on STN: 19990129
 Entered Medline: 19720407

CT Check Tags: Comparative Study
 Acetates: ME, metabolism
 Acetic Acids: ME, metabolism
 *Carbon Isotopes
 Culture Media
 Fermentation
 *Fusidic Acid: BI, biosynthesis
 Glucose: ME, metabolism
 Mitosporic Fungi: ME, metabolism
 Radioactivity
 Sodium: ME, metabolism
 RN 50-99-7 (Glucose); 6990-06-3 (Fusidic Acid); 7440-23-5 (Sodium)
 CN 0 (Acetates); 0 (Acetic Acids); 0 (Carbon Isotopes); 0 (Culture Media)

L55 ANSWER 25 OF 37 MEDLINE on STN
 AN 71288112 MEDLINE
 DN PubMed ID: 4398281
 TI [A method for preparing radioactive labeled phosphatides using soybeans in vivo].
 Uber eine in-vivo-Methode zur Herstellung radioaktiv markerter Phosphatide mit Sojabohnen.
 AU Holzl J; Wagner H
 SO Zeitschrift fur Naturforschung. Teil B: Chemie, Biochemie, Biophysik, Biologie, (1971 May) 26 (5) 425-34.
 Journal code: 0364315. ISSN: 0044-3174.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197111
 ED Entered STN: 19900101
 Last Updated on STN: 19980206
 Entered Medline: 19711112

CT Acetates: ME, metabolism
 Carbon Isotopes
 Choline: ME, metabolism
 Fatty Acids: ME, metabolism
 Glycerol: ME, metabolism
 Methods
 Phosphates: ME, metabolism
 Phosphatidylcholines: BI, biosynthesis
 Phosphatidylethanolamines: BI, biosynthesis
 *Phospholipids: BI, biosynthesis
 Phosphorus Isotopes
 Radiation Effects
 *Radioisotopes
 Radiometry
 *Soybeans
 RN 56-81-5 (Glycerol); 62-49-7 (Choline)
 CN 0 (Acetates); 0 (Carbon Isotopes); 0 (Fatty Acids); 0 (Phosphates); 0 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0 (Phospholipids); 0 (Phosphorus Isotopes); 0 (Radioisotopes)

L55 ANSWER 26 OF 37 MEDLINE on STN
 AN 71090573 MEDLINE
 DN PubMed ID: 4322218
 TI Incorporation of 32P-orthophosphate into phospholipids by a toxigenic and a nontoxigenic strain of Aspergillus flavus.
 AU Gupta S R; Viswanathan L; Venkitasubramanian T A
 SO Mycopathologia et mycologia applicata, (1970 Dec 28) 42 (1) 137-44.
 Journal code: 7505688. ISSN: 0027-5530.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals

EM 197103
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19710312
 CT Check Tags: Comparative Study
 *Aflatoxins: BI, biosynthesis
 Aspergillus: AN, analysis
 Aspergillus: GD, growth & development
 *Aspergillus: ME, metabolism
 Chromatography, Thin Layer
 Culture Media
 Gels
 Glucose
 *Phosphates: ME, metabolism
 Phosphatidylcholines: BI, biosynthesis
 Phosphatidylethanolamines: BI, biosynthesis
 Phosphatidylinositols: BI, biosynthesis
 *Phospholipids: BI, biosynthesis
 Phosphorus: AN, analysis
 *Phosphorus Isotopes
 Saccharomyces
 Silicon Dioxide
 Species Specificity
 Sucrose
 RN 50-99-7 (Glucose); 57-50-1 (Sucrose); 7631-86-9 (Silicon Dioxide);
 7723-14-0 (Phosphorus)
 CN 0 (Aflatoxins); 0 (Culture Media); 0 (Gels); 0 (Phosphates); 0
 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0
 (Phosphatidylinositols); 0 (Phospholipids); 0 (Phosphorus Isotopes)

 L55 ANSWER 27 OF 37 MEDLINE on STN
 AN 68157948 MEDLINE
 DN PubMed ID: 5237893
 TI On the constancy of deuterium fractionation in the biosynthesis of fatty
 acids since the miocene period.
 AU Zborowski G; Ponticorvo L; Rittenberg D
 SO Proceedings of the National Academy of Sciences of the United States of
 America, (1967 Oct) 58 (4) 1660-3.
 Journal code: 7505876. ISSN: 0027-8424.
 Report No.: NASA-68157948.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Space Life Sciences
 EM 196805
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19680501
 CT Amino Acids: AN, analysis
 Animals
 *Biogenesis
 California
 Chromatography, Gas
 *Deuterium: AN, analysis
 Fatty Acids: AN, analysis
 *Fatty Acids: BI, biosynthesis
 Fishes
 Geology
 Lipids: AN, analysis
 Rats
 West Indies
 RN 7782-39-0 (Deuterium)
 CN 0 (Amino Acids); 0 (Fatty Acids); 0 (Lipids)

 L55 ANSWER 28 OF 37 MEDLINE on STN
 AN 67216680 MEDLINE

DN PubMed ID: 5974909
 TI Fatty acid synthesis and gluconeogenesis in rats fed a high caloric diet.
 AU Shigeta Y; Oji N; Hoshi M; Kang M
 SO Metabolism: clinical and experimental, (1966 Aug) 15 (8) 761-6.
 Journal code: 0375267. ISSN: 0026-0495.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196710
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19671020
 CT Check Tags: In Vitro
 *Acetates: ME, metabolism
 Alanine: ME, metabolism
 Animals
 Blood Glucose: BI, biosynthesis
 Carbon Dioxide
 *Carbon Isotopes: ME, metabolism
 *Diet
 *Fatty Acids: BI, biosynthesis
 *Gluconeogenesis
 Liver Glycogen: BI, biosynthesis
 Rats
 RN 124-38-9 (Carbon Dioxide); 56-41-7 (Alanine)
 CN 0 (Acetates); 0 (Blood Glucose); 0 (Carbon Isotopes); 0 (Fatty Acids); 0
 (Liver Glycogen)

L55 ANSWER 29 OF 37 MEDLINE on STN
 AN 67202029 MEDLINE
 DN PubMed ID: 4291569
 TI The distribution of tritium in fatty acids synthesized from tritiated
 glucose and tritiated water by rat adipose tissue.
 AU Foster D W; Katz J
 SO Biochimica et biophysica acta, (1966 Dec 7) 125 (3) 422-7.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196709
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19670925
 CT Check Tags: Male
 *Adipose Tissue: ME, metabolism
 Animals
 Carbon Isotopes
 Epididymis
 *Fatty Acids: BI, biosynthesis
 *Glucose: ME, metabolism
 *Hydrogen: ME, metabolism
 *NAD: ME, metabolism
 Palmitic Acids: BI, biosynthesis
 Rats
 Stearic Acids: BI, biosynthesis
 *Tritium: AN, analysis
 Water
 RN 10028-17-8 (Tritium); 1333-74-0 (Hydrogen); 50-99-7 (Glucose); 53-84-9
 (NAD); 7732-18-5 (Water)
 CN 0 (Carbon Isotopes); 0 (Fatty Acids); 0 (Palmitic Acids); 0 (Stearic
 Acids)

L55 ANSWER 30 OF 37 MEDLINE on STN
 AN 67179526 MEDLINE

DN PubMed ID: 5971049
 TI Sites of control of hepatic cholesterol biosynthesis.
 AU Gould R G; Swyryd E A
 SO Journal of lipid research, (1966 Sep) 7 (5) 698-707.
 Journal code: 0376606. ISSN: 0022-2275.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196709
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19670907
 AB An inhibition in the conversion of mevalonate to cholesterol has been demonstrated in liver of cholesterol-fed rats by both in vitro and in vivo methods. Synthesis decreased to 30% of the control value after 1 week and 20% after 1 month on a 1% cholesterol diet. After a year, synthesis from mevalonate was almost completely inhibited. The rate of conversion of squalene to cholesterol was not consistently decreased but that of farnesyl pyrophosphate to cholesterol was decreased considerably. The rate of conversion of mevalonate to farnesyl pyrophosphate by a soluble liver enzyme preparation was also decreased in cholesterol-fed animals. Sites of inhibition of cholesterol synthesis were detected before mevalonate, between mevalonate and farnesyl pyrophosphate, and after farnesyl pyrophosphate, probably at the conversion of farnesyl pyrophosphate to squalene. The inhibition of mevalonate conversion to cholesterol developed more slowly than that of acetate and appeared to be secondary to it. The maximum capacities of normal liver homogenates and slices to synthesize cholesterol from mevalonate were shown to be far greater than from acetate. Consequently, sites of inhibition after mevalonate probably do not have a significant effect on the over-all rate of cholesterol synthesis in the intact cholesterol-fed animal.
 CT Check Tags: Male
 Animals
 *Carbon Isotopes
 Cholesterol: AN, analysis
 *Cholesterol: BI, biosynthesis
 Liver: AN, analysis
 *Liver: ME, metabolism
 Mevalonic Acid: ME, metabolism
 Rats
 RN 150-97-0 (Mevalonic Acid); 57-88-5 (Cholesterol)
 CN 0 (Carbon Isotopes)
 L55 ANSWER 31 OF 37 MEDLINE on STN
 AN 67160888 MEDLINE
 DN PubMed ID: 5965303
 TI Simultaneous P32- and C14-labeling of phospholipids by germinating soybeans.
 AU Hoelzl J; Wagner H
 SO Journal of lipid research, (1966 Jul) 7 (4) 569-70.
 Journal code: 0376606. ISSN: 0022-2275.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196707
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19670721
 AB Doubly labeled ((32)P and (14)C) phospholipids of high specific activity are obtained by incorporating the labels during germination of soybeans.
 CT Check Tags: In Vitro
 Acetates: ME, metabolism
 *Carbon Isotopes: ME, metabolism
 Phosphates: ME, metabolism

*Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism
 *Plants, Edible: ME, metabolism
 CN 0 (Acetates); 0 (Carbon Isotopes); 0 (Phosphates); 0 (Phospholipids); 0 (Phosphorus Isotopes)

L55 ANSWER 32 OF 37 MEDLINE on STN
 AN 67126401 MEDLINE
 DN PubMed ID: 4289988
 TI Effect of TSH, acetylcholine, epinephrine, serotonin and synkavite on 32-P incorporation into phospholipids in dog-thyroid slices.
 AU Altman M; Oka H; Field J B
 SO Biochimica et biophysica acta, (1966 Jun 1) 116 (3) 586-8.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196705
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19670522
 CT Check Tags: In Vitro
 *Acetylcholine: PD, pharmacology
 Animals
 Atropine: PD, pharmacology
 Dogs
 *Epinephrine: PD, pharmacology
 Phosphatidylcholines: BI, biosynthesis
 Phosphatidylethanolamines: BI, biosynthesis
 Phosphatidylinositols: BI, biosynthesis
 *Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism
 Puromycin: PD, pharmacology
 *Serotonin: PD, pharmacology
 *Thyroid Gland: DE, drug effects
 *Thyroid Gland: ME, metabolism
 *Thyrotropin: PD, pharmacology
 *Vitamin K: PD, pharmacology
 RN 12001-79-5 (Vitamin K); 50-67-9 (Serotonin); 51-43-4 (Epinephrine); 51-55-8 (Atropine); 51-84-3 (Acetylcholine); 53-79-2 (Puromycin); 9002-71-5 (Thyrotropin)
 CN 0 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0 (Phosphatidylinositols); 0 (Phospholipids); 0 (Phosphorus Isotopes)

L55 ANSWER 33 OF 37 MEDLINE on STN
 AN 67061525 MEDLINE
 DN PubMed ID: 6016079
 TI Iodide transport: inhibition by agents reacting at the membrane.
 AU Larsen P R; Wolff J
 SO Science, (1967 Jan 20) 155 (760) 335-6.
 Journal code: 0404511. ISSN: 0036-8075.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196703
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19670310
 CT Check Tags: In Vitro
 Animals
 *Antibiotics, Antifungal: PD, pharmacology
 Cattle
 *Iodides: ME, metabolism
 *Lysophosphatidylcholines: PD, pharmacology

*Phospholipases: PD, pharmacology
 *Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism
 *Potassium: ME, metabolism
 *Thyroid Gland: ME, metabolism
 *Thyrotropin: PD, pharmacology
 *Venoms: PD, pharmacology
 RN 7440-09-7 (Potassium); 9002-71-5 (Thyrotropin)
 CN 0 (Antibiotics, Antifungal); 0 (Iodides); 0 (Lysophosphatidylcholines); 0
 (Phospholipids); 0 (Phosphorus Isotopes); 0 (Venoms); EC 3.1.-
 (Phospholipases)

L55 ANSWER 34 OF 37 MEDLINE on STN
 AN 67004390 MEDLINE
 DN PubMed ID: 4287973
 TI Studies on brain phospholipids. IV. Post-mortem breakdown of
 phosphoinositides and phosphatidic acid, and P32-incorporation into
 phospholipids in various states of the tissue.
 AU Hayashi K; Yagihara Y; Nakamura I; Yamazoe S
 SO Journal of biochemistry, (1966 Jul) 60 (1) 42-51.
 Journal code: 0376600. ISSN: 0021-924X.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196611
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19661129
 CT Check Tags: In Vitro
 Animals
 *Brain: ME, metabolism
 Chemistry, Analytical
 Chromatography
 Guinea Pigs
 Ouabain: PD, pharmacology
 *Phosphatidylinositols: ME, metabolism
 *Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism
 Sodium: PD, pharmacology
 RN 630-60-4 (Ouabain); 7440-23-5 (Sodium)
 CN 0 (Phosphatidylinositols); 0 (Phospholipids); 0 (Phosphorus Isotopes)

L55 ANSWER 35 OF 37 MEDLINE on STN
 AN 67003285 MEDLINE
 DN PubMed ID: 5912364
 TI Perfusion in situ with tritium oxide to measure hepatic lipogenesis and
 lipid secretion. Normal and orotic acid-fed rats.
 AU Windmueller H G; Spaeth A E
 SO Journal of biological chemistry, (1966 Jun 25) 241 (12) 2891-9.
 Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196611
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19661127
 CT Animals
 *Cholesterol: BI, biosynthesis
 *Fatty Acids: BI, biosynthesis
 Hyperlipidemia: CI, chemically induced
 *Lipids: BI, biosynthesis
 *Liver: ME, metabolism
 *Orotic Acid: PD, pharmacology

Perfusion
 Rats
 Surface-Active Agents: PD, pharmacology
 Triglycerides: BL, blood
 *Tritium: ME, metabolism
 RN 10028-17-8 (Tritium); 57-88-5 (Cholesterol); 65-86-1 (Orotic Acid)
 CN 0 (Fatty Acids); 0 (Lipids); 0 (Surface-Active Agents); 0 (Triglycerides)

L55 ANSWER 36 OF 37 MEDLINE on STN
 AN 66157647 MEDLINE
 DN PubMed ID: 5940930
 TI Phospholipid metabolism in kidney. 3. Biosynthesis of phospholipids from radioactive precursors in rabbit renal cortex slices.
 AU Tinker D O; Hanahan D J
 SO Biochemistry, (1966 Feb) 5 (2) 423-35.
 Journal code: 0370623. ISSN: 0006-2960.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196610
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19661001
 CT Check Tags: In Vitro
 Animals
 Chromatography, Thin Layer
 Cyanides: PD, pharmacology
 *Glucose: ME, metabolism
 *Kidney: ME, metabolism
 *Linoleic Acids: ME, metabolism
 Ouabain: PD, pharmacology
 *Palmitic Acids: ME, metabolism
 Phosphatidylcholines: BI, biosynthesis
 Phosphatidylethanolamines: BI, biosynthesis
 *Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism
 Rabbits
 *Serine: ME, metabolism
 Sphingomyelins: BI, biosynthesis
 RN 50-99-7 (Glucose); 56-45-1 (Serine); 630-60-4 (Ouabain)
 CN 0 (Cyanides); 0 (Linoleic Acids); 0 (Palmitic Acids); 0 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0 (Phospholipids); 0 (Phosphorus Isotopes); 0 (Sphingomyelins)

L55 ANSWER 37 OF 37 MEDLINE on STN
 AN 66071506 MEDLINE
 DN PubMed ID: 4285354
 TI Biochemical changes in denervated skeletal muscle. 3. The effect of denervation atrophy on the concentration and 32P labelling of the individual phospholipids of the rat gastrocnemius.
 AU Graff G L; Hudson A J; Strickland K P
 SO Biochimica et biophysica acta, (1965 Jul 8) 104 (2) 543-53.
 Journal code: 0217513. ISSN: 0006-3002.
 Report No.: NASA-66071506.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Space Life Sciences
 EM 196603
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19660326
 CT Check Tags: In Vitro
 Animals
 *Muscle Denervation

*Muscles: ME, metabolism
*Muscular Atrophy: ME, metabolism
 Phosphatidylinositols: BI, biosynthesis
 *Phospholipids: BI, biosynthesis
 *Phosphorus Isotopes: ME, metabolism

Rats

CN 0 (Phosphatidylinositols); 0 (Phospholipids); 0 (Phosphorus Isotopes)

=> b home

FILE 'HOME' ENTERED AT 11:15:48 ON 10 JUN 2005

=>